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ABSTRACT 
The purpose of our investigation was to evaluate the efficacy of prophylactic 
interventions consisting of simulated exercise (high-impact, free-fall loading) and/or a 
bisphosphonate (zoledronic acid), to counter disuse-induced bone loss of adult male rats 
(6 months old) subjected to 28 days of hindlimb unloading.  Furthermore, we aimed to 
define the effects of these treatments on mechanical strength properties and bone 
turnover.  We hypothesized that monotherapy would mitigate adverse alterations in bone 
mass, microarchitecture, and strength, while the combined sequential treatment would 
completely prevent them.  Animals were assigned to one of six groups (n=12 each): 
baseline control (BC, euthanized on study day 0), cage control (CC), hindlimb unloading 
(HU), zoledronic acid treatment plus hindlimb unloading (ZA+HU), simulated exercise 
treatment plus hindlimb unloading (Ex+HU), and simulated exercise and zoledronic acid 
treatments plus hindlimb unloading (Ex+ZA+HU).  Ex animals were dropped 25 times 
(five drops from 30 cm followed by 20 drops from 60 cm) three times per week for the 
first five weeks of the study.  ZA (60 µg/kg body weight) was administered on day 36, 
immediately following Ex and just prior to HU.  HU began on day 37 and persisted for 
four weeks. 
At the distal femur metaphysis (DFM), proximal tibia metaphysis (PTM), and 
femoral neck (FN), HU caused declines in cancellous bone volume fraction (BV/TV, -
25%) and total volumetric bone mineral density (vBMD, -4.7% and -14%), respectively, 
compared to CC.  Mechanical strength and bone turnover were also impaired due to 
unloading.  Individually, Ex and ZA attenuated HU-induced changes in mass, 
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microarchitecture, and strength, but when given sequentially, Ex+ZA fully rescued them.  
While HU caused an uncoupling of bone remodeling, ZA treatment successfully reduced 
bone degradation without affecting bone formation.  Treatment with Ex followed by ZA 
resulted in enhanced DFM BV/TV (+20%) and trabecular thickness (Tb.Th, +5%), and 
PTM total vBMD (+13%).  Also, FN ultimate force was highest with combination 
treatment.  While Ex and ZA alone attenuated the deleterious effects of disuse on bone 
quality, when the two were administered in sequence adult male rats were fully protected 
against HU-induced alterations in bone mass, microarchitecture, strength, and turnover.         
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CHAPTER I  
 
INTRODUCTION 
 
Composition and Structure of Bone 
 Bone is a dynamic tissue comprised of various cells and an extracellular matrix.  
The extracellular, or organic, matrix of bone consists primarily of Type I collagen fibers 
(90%) and noncollagenous proteins (10%).  Along with cells and water, the organic 
matrix makes up 35% of bone and provides strength and resilience.  Minerals, consisting 
mainly of small needle- or plate-like crystals of hydroxyapatite, make up the remaining 
65% of bone, and are fixated on collagen fibers (1).  The orientation of hydroxyapatite 
crystals, normally parallel to collagen fibers, adds rigidity and compressive strength to 
bone (2).  The organization of collagen fibers in mammalian bones gives rise to two 
main types of bone structure: woven and lamellar.  Woven bone, a randomly oriented 
matrix of collagen fibers, is found mostly during bone development and fracture repair 
(2).  Unlike lamellar bone, which consists of preferentially organized layers of collagen 
fibers, woven bone is laid down quickly and is structurally weak (3).  In humans, woven 
bone is replaced by lamellar bone within approximately 2 and 3 years of age (1). 
 The human skeleton is made up of both cortical (compact) and cancellous 
(spongy) bone. In cortical bone, osteocytes and the extracellular matrix aggregate 
concentrically around Haversian canals forming cylindrical units called osteons (Figure 
1).   Densely packed osteons create the compact structure of cortical bone and are 
preferentially oriented to resist compressive forces (4).    Found primarily in the walls of 
the diaphysis, cortical bone is a solid tissue with only microscopic pores which contain 
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osteocytes, canaliculi, and blood vessels (Figure 1) (3).  Cortical bone makes up 
approximately 80% of the adult skeleton and serves in both mechanical support and 
organ protection (1).  Cancellous bone also consists of osteocytes and an extracellular 
matrix but differs from cortical bone in its porosity.  Rather than forming dense 
concentric clusters around a Haversian system (osteon), cancellous bone consists of 
highly porous irregular networks of plates and rods, called trabeculae (Figure 1) (4).  
Cancellous bone makes up approximately 20% of the adult skeleton and is located 
primarily in the regions of the epiphysis (Figure 1) (1).  Despite its relatively high degree 
of porosity, cancellous bone is both strong and mechanically resistant to bending.      
 
 
 
Figure 1. Cortical and Cancellous Bone: Human Bone Structure.  Public domain 
image obtained from (5). 
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The main cellular components of bone are osteoclasts, osteoblasts, lining cells, 
and osteocytes (1). Osteoclasts are highly differentiated, multinucleated cells, derived 
from the monocyte/macrophage lineage, which are responsible for the phagocytosis of 
bone (3).  Osteoblasts are responsible for replacing the erosion cavity that was created by 
the osteoclasts.  All of the matrix components of bone are laid down via osteoblasts (3).  
When osteoblasts are inactive, they become flattened and line the surface of bone.  
These quiescent osteoblasts are known as lining cells (3).  Much like osteocytes, which 
are trapped osteoblasts in newly formed osteoid, lining cells are influenced by stresses 
placed upon them, resulting in a release of chemicals which stimulate the activity of the 
bone remodeling process (1).  
Since twenty-four percent of adults in America over the age of fifty will die 
within one year following a major bone fracture, it is important to understand the 
relationship between the various cells within bone and the role these cells play in the 
reconstruction of microcracks throughout the skeleton (6).  Although the causes of said 
microcracks resulting in bone fractures range from decreased estrogen production in 
postmenopausal women to undesirable levels of mineralization in bone, the underlying 
problem is often the same: when the activity and balance of the major cellular 
components of bone remodeling are disrupted, the mechanical properties of bone are 
affected, ultimately resulting in increased fragility and fracture (7,8).   
Bone Remodeling 
The first stage of the bone remodeling process is resorption (9).  During 
resorption, osteoclasts degrade bone, creating an erosion cavity within the structure.  The 
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second stage, known as reversal, prepares the bone surface, via mononuclear cells, for 
the osteoblasts (1).  The third stage, therefore, is formation (9).  During formation, 
several osteoblasts are recruited to the erosion site and begin replacing the resorbed 
bone.  Upon completion of the formation phase of the bone remodeling process, 
osteoblasts secrete the cytokines Receptor Activator of Nuclear-Factor-kappa b Ligand 
(RANKL) and Osteoprotegerin (OPG).  RANKL binds to its receptor, RANK, expressed 
on the surface of osteoclasts and its precursor cells, stimulating osteoclast differentiation, 
activation, and bone resorption (10).  OPG is a soluble decoy receptor that competitively 
inhibits RANKL, disallowing RANK/RANKL interaction, ultimately maintaining a 
healthy balance between osteoclast survival and apoptosis (11).  An illustration of the 
OPG/RANKL secretion from osteoblasts is presented in Figure 2.  Since a healthy 
balance of RANKL/OPG dictates the fate of osteoclasts, and since osteoclasts affect the 
fate of osteoblasts due to coupling, it is clear how the RANKL/OPG ratio is essential to 
the overall health of bone.  
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Figure 2. OGP/RANKL Role in Remodeling.  Image obtained from (12) and used 
under permission of Fair Use (USC Title 17 SCC 107).   
 
 
The fourth, and final stage of the bone remodeling process, is resting (1).  During 
this stage of relatively little cellular activity, the bone lining cells await the appropriate 
signals to initiate another cycle of bone remodeling.   Figure 3 illustrates each step of the 
bone remodeling process and the major cells involved.  A tightly balanced relationship 
between the different stages of the bone remodeling process dictates the health of the 
bone.   
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Figure 3. Normal Bone Remodeling Process.  Reproduced with permission from (13). 
 
 
In a normal adult bone remodeling process, the activity of osteoblasts and 
osteoclasts is equal (14).  In pathological remodeling, however, an imbalance exists.  In 
osteopetrotic bone, for example, the activity of osteoblasts outweighs that of the 
osteoclasts, resulting in undesirably thick bones (15).  This over-activity of osteoblasts 
results in increased mineralization, brittleness, and fragility.  Conversely, osteoporotic 
bone experiences an increase in bone resorption and a decrease in bone formation (16).  
This imbalance leads to increased porosity, decreased bone mass, strength, and 
resistance to fracture.  Therefore, it is imperative that osteoblasts and osteoclasts 
contribute equally in remodeling to maintain desirable mechanical properties.   
Osteoclasts 
Osteoblasts 
Mononuclear 
Cells 
Lining Cells 
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 Much like the relationship that osteoblast and osteoclast activity has on bone 
health, the rate at which bone is replaced also plays a significant role.  This rate of 
replacement, known as turnover, is the time it takes osteoclasts to begin resorbing the 
bone previously laid down by osteoblasts (Figure 4).  In the initial, or primary, stage of 
turnover, the collagen matrix is formed (8).  In time, the collagen matrix is allowed to 
mineralize, providing more rigidity to the bone structure.  This mineralization 
predominates in the secondary phase of turnover.  Alterations in bone turnover often 
result in pathological remodeling (8).  In Paget’s disease, for example, there exists an 
increase in bone turnover.  As a result, the collagen matrix is not provided adequate time 
to mineralize, resulting in abnormally soft bones.  At the opposite extreme, when bone 
turnover is decreased, the collagen matrix becomes over mineralized, resulting in 
increased brittleness.  This type of hypermineralization can be found in osteopetrotic 
bone (14).  Changes in remodeling and turnover are also the result of alterations in 
mechanical environment.  Indeed, loads imposed on the skeleton dictate bone mass, 
geometry, and strength.       
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Figure 4. Bone Turnover.  During stages of high turnover, such as what is experienced 
post menopause, both resorption and formation increase, with resorption outweighing 
that of formation.  Similarly, during stages of low turnover, both resorption and 
formation decrease with a net positive effect of resorption. 
 
 
Wolff’s Law to the Mechanostat 
In the nineteenth century, Julius Wolff illustrated the interplay between the form 
and function of bone and its internal architecture.  In other words, the mechanical 
environment of bone dictates bone geometry and development.  This novel idea was the 
foundation of his Transformationsgesetz (Transformation Law) (17).  Although looked 
upon by anatomists and orthopaedics for hundreds of years in an effort to answer 
anatomical and physiological questions of bone health, Wolff’s Law was limited as a 
functional, rather than mechanistic, law and did not translate well into the clinical 
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setting.  Later, and still-evolving, evidence surfaced from live-animal studies conducted 
in Prof. Lee’s laboratory at the University of Utah and helped to resolve the Law’s 
limitations.  To wit: The driving biological mechanisms of healthy, postnatal, load-
bearing bones are strongly influenced by the anatomy and physiology of the 
neuromuscular system (18). The above Utah Paradigm provides a more clinically 
relevant proposal for the homeostasis of bone.  If muscle and bone are intimately linked 
by common mechanisms, two questions beg to be answered: What are the biological 
mechanisms of the functional muscle-bone unit?  And: How are these mechanisms 
monitored and controlled? 
 Mechanical stimulation on load-bearing bones causes the skeleton to deform.  
Osteocytes sense deformations, or changes in mechanical strain, and initiate a cascade of 
events responsible for determining bone strength and architecture.  In 1964, Harold Frost 
proposed a feedback loop linking biological mechanisms and bone mass (19). At the 
core of the feedback loop is the mechanostat.  As an analogy, consider an automatic 
thermostat.  When temperature values land above or below a predetermined value, or 
setpoint, the thermostat turns ON.  Otherwise, the thermostat remains OFF.  The 
setpoints of the mechanostat are measurements of strain, and the mechanisms turned ON 
and OFF are modeling and disuse remodeling.  When peak strain rises to a value 
between 1,500 and 2,500 microstrain, modeling is turned ON and cortical mass is 
increased.  By increasing cortical mass, peak strains are consequently lowered towards a 
threshold range, also known as minimum effective strain (MES).  Conversely, when 
peak strains dip below 100 to 300 microstrain, disuse remodeling is initiated.  Thus, 
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cortical mass is lowered, returning strain values back to MES. It is worth noting that 
during modeling, bone mass is almost exclusively added to the periosteal surface.  
During disuse remodeling, however, losses occur solely endocortically, or in the marrow 
area.  In post-menopausal women, the MES is thought to increase 30%, resulting in a 
mechanostat perception of 30% more bone than actuality (20).  With a higher MES, 
modeling is repressed while disuse remodeling is de-repressed.       
Musculoskeletal Disuse 
Revisiting Wolff’s Law, the size and strength of bone (form) depend on the 
mechanical environment that it senses it must withstand (function).  Therefore, when 
mechanical loading is removed, the activity of bone resorbing osteoclasts and bone 
forming osteoblasts becomes uncoupled, skewing the remodeling process in favor of 
resorption.  Data in support of this concept are manifest in spinal cord injury (SCI) 
patients, head down bed rest (HDBR) subjects, and astronauts.  SCI can cause reductions 
in femoral bone mineral density (BMD) of 25% or more within the first four months of 
injury (21).  Similar, although less dramatic, losses are evident in HDBR subjects, where 
12 weeks of bed rest lead to average losses of 3.8% BMD in the proximal femur (22). 
Twenty-eight days of hindlimb unloading (HU) in the rat model cause reductions of 8% 
or greater in proximal tibia BMD that persist for up to 112 days of normal ambulation 
(23).  Much like spaceflight, bone loss from SCI, HDBR, and HU is highly variable, 
site-specific, and well correlated with an increased susceptibility to fracture (24).  To 
counter this inherent limitation to long duration spaceflight, NASA designates 
considerable attention and effort to in-flight countermeasures.  Daily resistance exercise 
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on the Advanced Resistive Exercise Device (ARED) has provided the greatest protection 
for bone health to date (25). 
Exercise and Skeletal Anabolism 
Muscle contraction induced by resistance exercise is a well-documented method 
of improving bone health (26-30).  Forces produced on the skeleton by muscle 
contractions impart the largest physiological loads, and consequently the highest strains, 
on the skeleton (31).  These muscle-imparted bone strains strongly influence bone 
architecture and strength.  Thus, muscle size and strength are directly related and highly 
correlated to bone size and strength.  Regular physical exercise is highly recommended 
for both therapeutic and general health benefits.  Various types of exercise, such as 
dynamic versus non-dynamic, will result in different outcomes.  Weight-bearing 
activities, such as weight-lifting, running, dancing, and skiing, stimulate bone cells 
through muscle contractions and impact loading.  Less dynamic exercises, like 
swimming, cycling, and Tai chi, lack direct mechanical loads, and result in increased 
muscle balance and strength.  Although the precise amount of mechanical loading on the 
musculoskeletal system needed to promote growth remains unknown, it is largely 
accepted that a combination of resistance and aerobic, dynamic and non-dynamic 
activities, leads to improved muscle and bone health.  Physically active children, 
participating in both resistance and aerobic exercise, have been shown to exhibit higher 
bone accrual and maximum muscle forces compared to non-exercising controls (32,33).  
Similar exercise programs in adults do not always result in increased bone mass but do, 
however, help prevent absolute losses (34). 
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Bisphosphonates as Anti-Catabolic Therapy 
Another means of preventing, or slowing, bone loss in adults is through 
pharmacological interventions.   Anti-resorptive bisphosphonate (BP) treatment, for 
example, is the first-line therapy for prevention and treatment of osteoporosis.  Unlike 
resistance exercise, which increases bone mass and strength (anabolic), BPs slow down 
bone loss by decreasing the rate of resorption (anti-catabolic).  Within hours of 
administration, oral (alendronate, risedronate, etidronate) and injectable (zoledronic acid, 
ibandronate, and pamidronate) BPs bind to bone mineral (calcium), preferentially in 
active resorbing sites (35).  During bone resorption, osteoclasts ingest BPs bound to 
bone crystals, inhibiting their activity via a direct toxic effect and apoptosis (36).  
Differences in the anti-resorptive potency are dictated by the biochemical activity of the 
specific bisphosphonate.  For example, zoledronic acid’s (ZA) high kinetic binding 
affinity to bone mineral, coupled with its strong inhibition of the farnesyl pyrophosphate 
synthase enzyme, makes it currently the most potent anti-resorptive bisphosphonate 
available (37).   
In animal studies, both low- (4 – 20 µg/kg body weight) and high-dose (100 – 
500 µg/kg body weight) ZA treatment attenuated ovariectomy-induced (OVX , rodent 
model of postmenopausal osteoporosis) losses in total, cortical, and cancellous bone 
mass in the proximal tibia of adult virgin rats (38).  In fact, high-dose therapy augmented 
the aforementioned properties beyond baseline values and this effect persisted up to 32 
weeks beyond the single intravenous injection.  ZA has been shown to reduce the risk of 
new vertebral fractures by 70% for up to three years following a single injection (39).  
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As a result of coupling, however, these rapid reductions in bone resorption consequently 
lead to reductions in bone formation, thus suppressing turnover by reducing the 
inception of new remodeling units.  Unlike other medications, BPs remain bound to bone 
crystals for many years after cessation of treatment.  With a half-life of up to 10 years, 
BPs are capable of maintaining reduced remodeling rates long after discontinuation (40).      
Bone Densitometry and Morphometry 
 Densitometric parameters obtained from quantitative computed tomography 
(QCT) and micro computed tomography (µCT) allow for a three-dimensional 
assessment of bone architecture, structure, and geometry critical for estimating the 
overall health status of the skeleton.  Before discussing how disuse, exercise, and 
bisphosphonates affect bone densitometry and geometry, it is first worth exploring the 
basics of QCT and µCT in order to better understand how their derived indices are used 
to assess bone health.   
QCT assesses bone properties based on the interaction between X-ray photons 
and body tissue (41-43).  While dual-energy X-ray absorptiometry (DXA) yields two-
dimensional outcomes, such as areal BMD (aBMD), QCT is capable of producing three-
dimensional and compartment-specific (cortical and cancellous) properties of bone (e.g., 
volumetric BMD [vBMD]).  The ability of QCT to differentiate between cortical and 
cancellous bone is important clinically.  To begin, cancellous bone is eight times more 
metabolically active than cortical bone.  When assessing the efficacy of pharmacological 
countermeasures, for example, cancellous bone is likely to be affected before cortical 
bone.  Second, cancellous and cortical bone compartments can separately predict bone 
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fracture (44).   QCT is a measurement of radiographic absorptiometry-derived linear 
attenuation coefficients (LACs).  LACs correspond to the amount of X-rays absorbed by 
tissue taken at different angles.  These absorption measurements are recorded in a 
computer and combined by filtered back-projection.  Briefly, an X-ray source is 
transmitted through the patient along the length of the scanner to create a thin slice of 
tissue ranging from a fraction of a millimeter to several millimeters in thickness.  The X-
ray fan then circumscribes the patient 360° corresponding to a circular matrix of two-
dimensional square pixels.  Because these cross-sectional pixels correspond with a slice 
thickness, the picture elements are volumetric in measurement.  These volumetric 
elements, referred to as voxels, may be thought of as a three-dimensional pixel element.  
Altogether, as the X-ray source and detector rotate around the patient, the detector 
continuously measures the level of tissue absorption.  Absorption measurements are then 
translated to LACs representative of each voxel.  Since LACs vary between different 
QCT machines (due to different kilovoltage settings), the Hounsfield scale is used for 
standardization.  A Hounsfield unit (HU), which is the gray-scale value of each voxel, is 
defined as the ratio of the difference of the LAC of a given voxel and the LAC of water 
to the LAC of water.  HUs can be thought of as pixel brightness, and are sometimes 
reported in that way.  HUs are then calibrated to yield values of vBMD which, when 
combined with structural measures, have been shown to be associated with fracture in 
the hip, spine, and proximal femur (45-51).                
 HUs are calibrated with a solid calcium hydroxyapatite phantom and dedicated 
software.  Within the desired region of interest (ROI), linear regression analysis is used 
 15 
 
to determine a relationship between mean HU and known concentrations of bone-like 
material (calcium hydroxyapatite).  That is, HUs within an ROI (e.g., vertebra) are 
converted to a concentration (reported as mg/cm3) of bone-like material.  It is important 
to note that, unlike DXA areal BMD (aBMD), QCT yields a volumetric measurement of 
density (vBMD) and is thus independent of bone size.  QCT does, however, expose the 
patient to a relatively larger dose of radiation compared to other diagnostic X-ray exams.  
An X-ray mammography, for example, imparts an effective dose of approximately 0.6 
mSv to the breast (52), while doses from a QCT scan can range from 1 mSv to 6 mSv 
(53).  Although the level of true risk associated with radiation exposure from bone 
imaging techniques remains largely unknown, the potential risk for carcinogenesis is 
thought to be very small (53).   
 Over the past decade, the advantages of QCT in both the clinic and in research 
are becoming increasingly evident.  Although QCT is capable of determining three-
dimensional geometric bone properties, differentiating between cortical and cancellous 
bone, and generating volumetric density measurements, this imaging system is still 
limited by voxel size and spatial resolution.  In cancellous bone, for example, the size of 
a given voxel may be larger than the dimensions of a single trabecular strut.  
Consequently, the associated HU value for this voxel will include a combination of 
cancellous bone, collagen, and marrow.  Since the surrounding constituents of the 
trabecular strut are averaged into the calculation of the HU value, the mass of bone per 
unit tissue volume may be underestimated. This volume averaging, referred to as the 
partial volume effect, is the primary source of error in QCT imaging.  For analyses 
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requiring higher resolution, alternative options, such a micro computed tomography 
(µCT), which has a spatial resolution ranging from 1-100 µm (54), are available for use. 
Since the late 1980s, µCT has been used to investigate bone morphology and 
microarchitecture and is now considered the “gold standard” for ex vivo use in small 
animals.  With its increasing popularity for animal and human bone imaging, there is a 
growing need for standardization of µCT reporting.  Bouxsein and colleagues provide an 
excellent review presenting guidelines for consistent reporting of image acquisition, 
image evaluation, and outcomes (55).   
A standard desktop µCT device operates within a range of 20 - 100 kVp.  X-rays 
emitted from a micro-focus X-ray tube are transmitted through the test specimen at 
several viewing angels, rendering an attenuation projection onto a detector capable of 
generating a three-dimensional distribution of mineral density.  With its 
characteristically high resolution (voxel size as low as a few micrometers), individual 
mouse trabeculae, which can be as small as 30 µm in thickness, can be captured and 
quantified (56,57).  When capturing both trabecular and cortical microarchitecture and 
morphometry, µCT poses several advantages compared to traditional histomorphometric 
techniques.  First, µCT provides a larger volume of interest versus standard histology.  
Whereas histology may take several weeks/months to process a few tissues, µCT can 
produce data at multiple bone sites in a matter of minutes.  Thus, µCT permits a much 
higher throughput than histology.  Furthermore, since µCT analysis is nondestructive, 
subsequent testing can be performed (e.g., mechanical testing) corresponding to scan 
sites.   
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µCT is often favored over QCT because of its comparatively high resolution 
(small voxel size).  A tradeoff exists, however, for voxel size and scan time.  Smaller 
voxel sizes require longer scan times, exposing the tissue to higher doses of radiation.   
Scans lasting approximately 20 minutes (voxel size 10 µm) correspond to about 0.4 Gy 
of radiation incident upon the object tissue (58).  Although single scans are not 
considered to impart damage to bone cells, longitudinal scanning has been shown to 
affect trabecular bone volume as much as 8 - 20% (59).  When µCT analysis is used to 
investigate trabecular and cortical morphometry, a minimum set of parameters are 
considered necessary to report (55).  For trabecular bone, the variables include bone 
volume fraction (BV/TV; %), trabecular number (Tb.N; 1/mm), thickness (Tb.Th; mm), 
and separation (Tb.Sp; mm).  Total cross-sectional area (Tt.Ar; mm2), cortical bone area 
(Ct.Ar; mm2), cortical area fraction (Ct.Ar/Tt.Ar; %), and average cortical thickness 
(Ct.Th; mm) should be reported for cortical morphometry.   
 Three-dimensional model-independent algorithms can be used to calculate and 
quantitatively describe bone microarchitecture (60).  This method, referred to as 
quantitative morphometry, was achieved in the past by two-dimensional stereologic 
techniques.  Since the advent of µCT, however, variables such as Tb.Th and Tb.Sp take 
advantage of the three-dimensional capabilities of µCT.  Figure 5 illustrates how 
trabecular thickness and separation are determined using a three-dimensional sphere 
fitting method.   Briefly, three-dimensional spheres are fit along trabecular struts or 
inside marrow space to calculate measurements of Tb.Th and Tb.Sp, respectively.  Other 
trabecular parameters, such as connectivity density (Conn.D) and structure model index 
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(SMI), also yield important microarchitectural results.  Connectivity describes 1) number 
of objects, 2) number of marrow islands, and 3) number of connections that must be 
severed to completely cut bone into two separate parts.  Since connectivity is dependent 
on bone size, it is normalized by the volume of the bone to obtain Conn.D.  Finally, SMI 
is an index of trabecular bone structure indicating a perfect plate (0), a perfect rod (3), or 
a perfect sphere (4).  Conventionally, lower values of SMI indicate a more structurally 
sound tissue.  For cortical bone, µCT variables are often used as estimates of mechanical 
strength.  Average cross-sectional area (Tt.Ar), for example, particularly in mid-shaft 
bone, is associated with elastic modulus (i.e., resistance to a bending moment).  Tt.Ar is 
defined as the volume of interest divided by the number of slices and voxel height.  
Other important parameters include maximum (Imax), minimum (Imin), and polar (J) area 
moments of inertia.    
 
 
 
 
Figure 5. Method used for Calculating µCT Parameters. (A) trabecular thickness 
(Tb.Th) and (B) separation (Tb.Sp).  This direct three-dimensional method uses sphere 
fitting to obtain object thickness or separation.  Image obtained with permission from 
(55). 
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Numerous studies have used both QCT and µCT analyses to investigate the role 
of mechanical disuse on bone health, yet none have explored the sequential treatment of 
exercise followed by a bisphosphonate prior to unloading (61-68).  Furthermore, the 
potent anti-resorptive effects of ZA have not been explored in the HU rat model.  
Twenty-eight days of HU caused a 9.7% and 7.4% loss in proximal tibia metaphysis 
BMC and BMD, respectively (66).  Various exercise interventions have been used 
during and after HU to attempt the prevention of or the recovery from disuse-induced 
bone loss, yet recovery and prevention are often incomplete (69-80).  A head-to-head 
comparison of jump training versus treadmill running in HU rats concluded that 
trabecular number and connectivity remained suppressed in rats exercised with jumping 
while losses in trabecular thickness were not prevented with treadmill running (72).  
Mechanical stimulation via whole-body vibration treatment during 28-d HU in rats 
attenuated, but did not prevent, BMD loss in the tibia and femur (79).  Furthermore, 
vibration had zero effect on lumbar spine densitometry measures (79).   
Although limited, exercise interventions have proven efficacious to bone health 
and warrant further research to optimize its anabolic effect on the skeleton.  Astronauts 
aboard the International Space Station (ISS) currently dedicate over 2.5 hours each day 
to exercise.  With exercise alone, however, serial densitometric measurements taken 
upon return to Earth reveal sustained losses in the hip and spine that may persist for up 
to 4.5 years (81).  Thus, the combined role of exercise and bisphosphonate 
pharmaceuticals is now being explored on both the ISS and in research.  In HU rats, 
concurrent treatment of a bisphosphonate (alendronate) and exercise (simulated 
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resistance training [SRT]) has been performed.  Independently, alendronate suppressed, 
while SRT prevented, disuse-induced losses in total and cancellous BMD (82).  When 
combined, however, alendronate and SRT showed no additive benefits to BMD.  A 
similar study concluded that the combination of alendronate and SRT actually dulled the 
anabolic potential of the exercise intervention (83).  A potential explanation for this 
reaction lies in the anti-resorptive action of bisphosphonates.  With exercise and 
alendronate administered simultaneously, it is possible that the alendronate-induced 
suppression of bone turnover blunted the osteogenic potential of SRT.  That is, with less 
bone being laid down and removed, exercise was less effective when combined with 
alendronate at increasing BMD in the proximal tibia metaphysis.  Administering 
bisphosphonate therapy after an exercise intervention, rather than during, may work to 
sidestep the aforementioned blunting effect of reduced turnover on the anabolism of 
exercise.          
Biomechanical Assessment of Bone 
 Mechanics may be defined as the behavior of a material when subjected to an 
applied load.  When mechanics methods are employed to study a biological system, such 
as rat bone, the term biomechanics is often used.  Biomechanical testing has been used 
extensively in research to evaluate skeletal health, to test the efficacy of therapeutic 
interventions, and to predict fracture risk associated with bone loss.  At the core of 
biomechanical testing, and of which corresponding calculated indices derive, is force 
and displacement.   The relationship between the force applied to a material and the 
displacement of that material is called the load-deformation curve.  Load-deformation 
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curves provide valuable data, such as flexural rigidity, yield force, and ultimate load, but 
because they are based on the whole bone structure (i.e., not normalized for bone size 
and shape), only extrinsic properties can be determined.  In order to obtain intrinsic 
values, such as Young’s modulus, load-deformation curves must be converted to stress-
strain curves.   Stated differently, the rigidity (extrinsic stiffness) of bones of drastically 
different sizes will be much different, yet their Young’s modulus (intrinsic stiffness) will 
be quite similar.  Stress is typically defined as  
(1-1)     σ  
 
 
 ,  
where F is the applied load and A is the cross-sectional area.  Strain is a change in length 
over the original length, written as 
 
(1-2)     ε =  
  
 
 , 
and is thus unitless.   In order to use these basic, uni-axial equations, some assumptions 
must first be made.  Namely, bone is assumed to be an isotropic, homogenous, linearly 
elastic material with a uniform cross-sectional area.  Although bone is actually an 
anisotropic, non-homogeneous, viscoelastic, irregularly shaped structure, the 
aforementioned mathematical assumptions have been shown to be a reasonable 
approximation and allow for a much less complicated stress analysis (84,85).  In fact, 
these assumptions are considered standard practice in bone biomechanical testing and 
are used extensively in the literature (43,66,75,86-91).   
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 The stress-strain curve is divided by two regions: the elastic strain region and the 
plastic strain region.  The division of these two regions occurs at a theoretic boundary 
called the yield point (Figure 6).  In the elastic strain region, bone deformation is mostly 
recoverable.  That is, when loading is removed, bone will generally return to its original 
state.  In the plastic strain region, however, permanent deformation has occurred.  Once 
the stress-strain curve enters the plastic region, crack initiation, propagation, and fracture 
of the bone begins to occur.  Thus, the yield point, or yield stress, denotes unrecoverable 
deformation and damage.  Under tensile and compressive loading, the slope of the elastic 
strain region is called the Young’s modulus (E).  Ultimate strength is determined as the 
highest stress achieved by the material during testing.  This value often corresponds with 
the breaking strength but, in the case of bone, is commonly lower.  That is, deformation 
continues beyond the ultimate strength but stress begins to fall just before failure.  
Absorbed energy, or toughness, is another parameter often used to describe the behavior 
of materials during mechanical testing.  Toughness is defined as the area under the entire 
stress-strain curve, from the origin to the point of fracture, and describes the material’s 
resistance to fracture.  Brittle bone fails just after yielding because of an inherent low 
resistivity to fracture.   
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Figure 6.  Stress-Strain Curve. Top: Stress-strain curve separated by elastic strain 
region and plastic strain region.  Bottom: Stress-strain curve depicted with yield strength 
and ultimate/breaking strength.  Image obtained with permission from (85). 
 
 
 Several different biomechanical testing procedures can be used to test the overall 
strength of bone.  Basic three-point bending and microindentation testing, along with 
virtual finite element model (FEM) testing, will be discussed here.  The three-point 
bending technique tests bone strength in bending.  Figure 7 illustrates the general setup 
of a three-point bending test.  The span length, L, must be long enough to ensure loading 
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results primarily in bending and not in shear.  In mechanics, L should be 16 times larger 
than the thickness of the material.  With rodent bones, however, this 16:1 ratio is not 
practical, so a span ranging from 15-20 mm is conventionally used.  Based on the testing 
setup depicted in Figure 7, the following equations for stress, strain, and Young’s 
modulus, respectively, are obtained: 
(1-3)     σ = 
   
  
 ,    
where F is the applied load, L is the span length between the bottom supports, c is the 
distance from the center of mass, and I is the cross-sectional moment of inertia; 
(1-4)     ε = 
    
  
 , 
where d is the resulting displacement;  
(1-5)     E = 
 
 
  
   
 , 
where E is the ratio of stress to strain in the linear elastic region.  The value of I can be 
approximated by the moment of inertia equation for a hollow ellipse, but is more 
accurately obtained by digital imaging techniques such as QCT.  Finally, the ratio F/d is 
often referred to as the extrinsic stiffness, or the slope of the linear elastic region of the 
force-displacement curve, and can be expressed as a single quantity, k.       
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Figure 7.  Three-Point Bending Applied to a Rodent Bone.  F is the applied load.  d is 
the displacement of the bone.  L is the span length between the bottom supports.  Image 
obtained with permission from (85). 
 
 
 Although three-point bending tests provide valuable information about bone 
strength, it is a destructive test and is thus limited to ex vivo use only.  In order to obtain 
material properties from living tissue, non-destructive microindentation, or reference-
point indentation (RPI), allows for serial in vivo biomechanical tests to be performed and 
has even proven suitable in the clinical setting (88).  As described in Figure 8, the 
indentation procedure begins by inserting the probe onto the bone surface being testing.  
Once the periosteum is displaced by the reference probe, 20 indentation cycles are 
applied via the test probe.  The main outcome variable of the RPI test is Indentation 
Distance Increase (IDI), which is equal to the absolute penetration distance measured 
from the first cycle to the last cycle.  In theory, the less resistant bone is to indentation 
under loading, the more likely it is to fracture.  Thus, larger IDIs correspond to higher 
fragility and a consequent increased risk of fracture.  Although RPI is proving to be a 
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useful tool capable of quantifying in vivo bone material properties at the tissue level, it is 
limited by its inability to test bone as a composite.  That is, RPI can test either cortical or 
cancellous bone separately, but not together.  To non-destructively test composite bone, 
a computer-based mathematical technique known as finite element modeling (FEM) may 
be employed.        
 
 
 
Figure 8. Procedure for Reference-Point Indentation (RPI).  RPI test begins by 
inserting the probe assembly.  After the reference probe displaces the periosteum, the 
test probe cycles 20 times.  The major outcome variables are the Initial Indentation 
Distance and the Indentation Distance Increase which can be converted to parameters 
related to the material at the tissue level.  Image reproduced with permission from (88). 
 
 
 FEM begins by dividing CT-derived scan data into discrete pieces, or “finite 
elements” (FEs), to form an FE mesh (Figure 9) (92,93).  The FE mesh then undergoes 
three steps: 1) calculations of bone geometry by determining outer boundaries of the 
specimen, 2) estimates of bone material properties corresponding to each voxel, and 3) 
determination of failure loads and stress concentrations through simulated applied forces 
 27 
 
(94).  If 15 or more contiguous elements fail, a fracture is considered to occur.  In the 
instance of a failure, a factor of safety (i.e., strength divided by stress) of less than one is 
assigned to the tissue.  High correlation to measured failure loading (e.g., three-point 
bending mechanical testing) in both fall (r = 0.95) and stance (r = 0.96) loading 
conditions has been demonstrated (95).  While CT-derived FEM is most prevalent in 
research, Keyak and colleagues have developed a clinical application whereby patient-
specific FE models of the hip can be generated.     
 
 
 
Figure 9. Three-Dimensional Representation of a Finite Element (FE) Mesh. 
Displacement is being applied to the femoral neck as indicated by arrows applied at the 
top left corner of the femoral head.  Image generated by Keyak and colleagues and 
reproduced here with permission (96).   
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Bone Turnover: Relationship between Resorption and Formation 
 Bone turnover status is a key component in the overall assessment of bone 
quality.  Bisphosphonate therapy, for example, decreases bone resorption because of its 
potent anti-catabolic effect on osteoclasts.  Because of coupling, however, bone 
formation also declines, with an aggregate result of suppressed bone turnover.  In order 
to determine the rate at which osteoblastic formation occurs, standard bone 
histomorphometric techniques may be employed.  In accordance with the American 
Society for Bone and Mineral Research (ASBMR) Histomorphometry Nomenclature 
Committee, the following are the generally agreed upon nomenclature for bone 
histomorphometry (97). 
 The term “bone” may take on several meanings.  Generally, bone is considered to 
be an individual organ, or the hard tissue, that makes up the skeletal system.  Herein, 
bone will refer to both the mineralized and not yet mineralized (osteoid) matrix, 
excluding marrow and other soft tissue.  The combination of marrow, soft tissue, and 
bone matrix (mineralized and osteoid) is referred to as “bone tissue” or “tissue volume” 
(TV).  Other common referents in histomorphometry, along with TV, are bone surface 
(BS), bone volume (BV), and osteoid surface (OS).  Bone volume per tissue volume 
(BV/TV), for example, is the ratio of cancellous bone volume to tissue volume in a 
desired ROI.  It should be noted, however, that the term “volume” used in standard 
histomorphometry techniques is not a three-dimensional quantity.  Bone volume (BV) is 
defined as the area of bone within a two-dimensional ROI.  Along with BV/TV, other 
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structural indices can be determined from histomorphometry.  Trabecular number (Tb.N) 
is the number, or density, of individual trabeculae within the ROI, and is determined by 
(1-6)     Tb.N = 
  
  
    
 ,        
where Tb.Th represents trabecular thickness, calculated as 
(1-7)     Tb.Th = 
 
  
  
 . 
Trabecular separation (Tb.Sp) refers to the distance between edges of individual 
trabeculae, and is expressed as 
(1-8)     Tb.Sp = (Tb.N)-1 – Tb.Th. 
In subjects given label administration, kinetic indices can also be determined. 
 Dynamic bone histomorphometry yields valuable data from undecalcified 
sections of bone viewed under fluorescent microscopy.  Quickly after tetracycline 
antibiotics are administered, they become deposited onto sites of active bone formation.  
Sequential tetracycline injections, separated by a predetermined period of time, permits 
the measure of mineral apposition rate (MAR).  MAR is the linear distance between the 
midpoints of two labels divided by the time between administration of the labels.  Based 
on data from labeled surface (mineralized surface [MS]), total bone surface (BS), and 
MAR, bone formation rate (BFR) is computed as 
(1-9)     BFR = MAR x  
  
  
 .    
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BFR is a common parameter used to assess the status of bone formation following 
anabolic therapy.  Eight weeks of treadmill running in rats, for example, caused an 
increase in BFR of over 30% compared to sedentary control animals (98).   
 While histomorphometry provides valuable insight for the status of bone 
formation, bone resorption rate cannot be measured directly from this technique.  In 
order to assess bone resorption, biochemical markers, such as C-terminal cross-linking 
telopeptides of type I collagen (S-CTX), urinary free deoxypyridinoline (U-DPD), and 
serum tartrate resistant acid phosphatase (TRAcP) isoform 5b (TRAcP 5b) are often 
used.  Specifically, TRAcP 5b is gaining popularity as an indicator of osteoclast number 
and has shown to be a predictor of bone fracture in elderly women (99). 
 TRAcP is an enzyme expressed in inflammatory macrophages, dendritic cells, 
and osteoclasts.  TRAcP has two different isoforms within the blood: 5a, which is 
derived from macrophages and dendritic cells, and 5b, which is from actively resorbing 
osteoclasts (100).  TRAcP 5b functions as a regulator for the attachment of osteoclasts to 
bone matrix (101).  Transgenic mice exhibiting an overexpression of TRAcP 5b show 
rapid increases in bone resorption, decreases in cancellous bone, and the onset of a mild 
osteoporosis (102).  Using commercially available immunoassays for serum TRAcP 5b 
(e.g., BoneTRAP® and MetraTRACP5b®), serum concentrations of TRAcP 5b can be 
readily assessed in both the lab and the clinic.   
Separately, the effect of exercise, bisphosphonate therapy, and unloading on bone 
turnover has been extensively researched (69,74-76,78,83,86,103-109), yet the 
combination of exercise and bisphosphonate treatment administered prior to a period of 
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unloading has not been explored.  Furthermore, ZA, which is the most potent suppressor 
of bone resorption currently available, has not been tested prior to HU in rats.   Fourteen 
days of HU in growing rats caused a 48% decline in periosteal MAR and a 35% increase 
in urinary bone resorption markers versus control animals (110).  Although treatment 
with a bisphosphonate (pamidronate) was able to reduce bone resorption, since it was 
unable to prevent declines in formation, losses in cortical mass and strength were not 
prevented.  A similar study conducted in mice revealed that two weeks of HU caused a 
45% reduction in total BFR (111).  Adding ZA further suppressed total BRF by 42%.  
Although bisphosphonates act solely on osteoclasts, this reduction in osteoblast activity 
may be explained by bone coupling.  Since osteoclasts and osteoblasts operate in unison, 
the suppression of one can potentiate the inhibition of the other.         
In order to combat declines in bone formation that occur with disuse, exercise 
interventions are often employed during a period of unloading.  Dynamic muscle 
stimulation in HU rats was evaluated to determine whether disuse osteoporosis could be 
prevented by daily induced muscle contractions (74).  Although losses in cancellous 
bone were mitigated, daily muscle stimulation did not prevent declines in bone 
formation.  Since exercise and bisphosphonate treatments administered separately yield 
often incomplete recovery and/or prevention of disuse bone loss, the combination 
treatment of exercise (SRT) and a bisphosphonate (alendronate) has been explored 
(82,83).  Separately, SRT caused an increase in BFR, while alendronate caused a 
decrease in serum TRAcP 5b.  TRAcP 5b was not further reduced nor was BFR further 
increased, however, when SRT was used in combination with alendronate.  In fact, the 
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data suggest that alendronate therapy actually impaired the osteogenic response from 
SRT.  It should be noted, however, that SRT and alendronate were administered 
simultaneously.  That is, exercise was performed during a suppressed state of bone 
turnover.  Because turnover was reduced, the skeletal anabolism of exercise may have 
been blunted.  Future research is needed to elucidate the combined role of exercise and 
bisphosphonates administered sequentially, rather than simultaneously, so exercise is 
performed prior to a decreased state of turnover.             
Combining Simulated Exercise with Zoledronic Acid: Better Together? 
Because they have two distinct mechanisms of action, the anabolic potential of 
exercise, along with the anti-catabolic effect of BPs, may perhaps work in combination 
when administered together during or prior to a period of mechanical disuse.  Although 
previous studies have aimed to illuminate the additive potential of exercise and BPs on 
bone health (82,83,112-114), the combined effect of exercise and BP interventions prior 
to HU in rats has not been investigated.  Furthermore, no studies to the author’s 
knowledge have explored the potent anti-resorptive effect of ZA, alone or in 
combination with exercise, in the HU rat model.  A review of the literature reveals an 
equivocal understanding of the combined effect of exercise and BP treatment.  Fuchs et 
al. demonstrated additive interactions between exercise (treadmill running) and 
alendronate administration on bone densitometric and strength properties in OVX rats 
(113).  Similarly, BP treatment (risedronate, alendronate, or zoledronate) did not inhibit 
bone growth in OVX mice when mechanically loaded (112).  Compared to BP alone, 
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bone formation rate was enhanced when BP and loading were used in combination 
(Figure 10).  
 
 
 
Figure 10. Periosteal Bone Formation Rate (BFR). BFR affected by BP Treatment 
and Loading after OVX.  Among groups, no significant differences exist for non-loaded 
BFR.  For all BP groups, loading significantly increased BFR compared to non-loading 
(p<0.05).  VEH = placebo treated; RIS1,2 and RIS2,4 = risedronate groups; ALN = 
alendronate groups; ZOL = zoledronate groups.  Image obtained with permission from 
(112). 
   
 
Lung transplant recipients (LTR), a population highly susceptible to rapid bone 
loss and heightened fracture risk (via prolonged glucocorticoid therapy), experienced 
additive benefits of resistance exercise and BP (alendronate) therapy (Figure 11) (115).  
As Figure 11 reveals, untreated LTR suffered a decline in BMD (-12.5%) at the lumbar 
vertebra two months post-transplant.  Although BP treatment alone was able to maintain 
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BMD levels (+1.4%), the combination of BP with once-weekly resistance exercise was 
osteogenic (+10.3%).    
 
 
 
Figure 11. Change in Lumbar Vertebral BMD. Data assessed in lung transplant 
patients.  BP treatment began seven days after transplantation and prevented BMD 
losses.  Resistance exercise began, with and without BP, at two months post-transplant 
and ceased at eight months.  Combined treatment led to an anabolic response.  *indicates 
significant differences (p≤0.05) versus pre-transplantation (Pre-TX); +indicates 
significant differences (p≤0.05) versus alendronate and control.  Image obtained with 
permission from (115). 
 
 
Recent data from the International Space Station reveal a promising effect of BPs 
taken before and during in-flight missions (116).  Compared to controls, declines in 
BMD at the proximal femur and lumbar spine are drastically reduced with BP treatment.  
Although the data are encouraging, confounding factors in the control groups (i.e., use of 
the interim Resistive Exercise Device (iRED) in the controls versus the Advanced 
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Resistive Exercise Device (ARED) in the BP group) exist and make interpretation of 
these results challenging.  Thus, the combined role of BP and exercise remains unclear.   
Ground-based animal studies of disuse in HU rodents treated with a BP 
(alendronate) and exercise (SRT) have been performed in our laboratory.  Swift et al. 
demonstrated a marked increase in bone architectural properties and bone formation rate 
when SRT, alone or in combination with BP, was administered during HU (Figure 12) 
(82).  This study found that BP treatment, however, blunted the osteogenic effects of 
SRT.  That is, SRT treatment alone yielded higher gains in cancellous bone formation 
versus SRT combined with BP, although both groups exhibited significant gains in BFR 
relative to weight bearing controls.  Macias et al. found a similar hindrance of bone 
formation with the SRT and BP combination on periosteal bone surfaces (83).        
It is noteworthy to mention, however, that the impact of these treatments on bone 
resorption remains largely unknown.  Since the SRT and BP therapies were introduced 
after HU was initiated, it can likely be assumed that bone remodeling was uncoupled 
with HU (before the initiation of treatment).  Thus, even though bone formation was 
greatest in the HU+SRT group, HU+SRT/ALEN may have produced a more favorable 
balance of osteoclast and osteoblast activity.   
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Figure 12. Cancellous Bone Formation Rate.  BFR assessed with or without 
alendronate (ALEN) treatment and/or simulated resistance training (SRT) taken at the 
proximal tibia metaphysis.  Groups not sharing the same letter are significantly different 
(p<0.05). †indicates significant difference versus CC (P<0.05).  Image obtained with 
permission from (82). 
 
 
The current study was conceived and developed to seek a better understanding of 
the interactions between simulated exercise, BPs, and disuse.  By administering high-
impact, free-fall simulated exercise first, we forecasted that bone formation would be 
enhanced without interference from ZA.  That is, because BPs reduce turnover, they 
have the potential to reduce the anabolism of exercise.  Thus, by incorporating simulated 
exercise prior to ZA treatment, our first hypothesis was that Ex would increase bone 
formation and mitigate disuse-induced alterations in bone mass, density, 
microarchitecture, and strength in the hindlimbs of adult rats subjected to 28 days of 
musculoskeletal disuse.  Similarly, we hypothesized that ZA monotherapy (ZA+HU), 
because of its potent reduction of bone resorption, would lower bone resorption and 
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mitigate the aforementioned losses resulting from HU.  Our final hypothesis was that the 
sequential, combination treatment (Ex+ZA+HU) would completely prevent alterations in 
bone mass, density, microarchitecture, and strength in the hindlimbs of adult rats 
subjected to 28 days of musculoskeletal disuse.   
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CHAPTER II  
 
MATERIALS AND METHODS 
 
Animals and Experimental Design 
 Adult male Sprague-Dawley rats were obtained from Harlan Laboratories 
(Houston, TX) at 5.5 months of age and singly housed in a temperature-controlled (23 ± 
2 ºC) room with a 12-hour light-dark cycle (9PM-9AM) in an AAALAC-accredited 
animal care facility.  Animals were provided standard rodent chow (Harlan Teklad 8640) 
and water ad-libitum.  Animal care and all experimental procedures described in this 
study were conducted in accordance with the Texas A&M University Institutional 
Animal Care and Use Committee rules and approvals. 
 After 14 days of acclimation, animals were block assigned to groups normalized 
by body weight (Figure 13).  Animals (n=72) were assigned to one of six categories 
(n=12 each): baseline control (BC, euthanized on study day 0), cage control (CC), 
hindlimb unloading (HU), zoledronic acid treatment plus hindlimb unloading (ZA+HU), 
free-fall simulated exercise treatment plus hindlimb unloading (Ex+HU), and free-fall 
simulated exercise and zoledronic acid treatments plus hindlimb unloading 
(Ex+ZA+HU).  
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Figure 13. Experimental Design. X = Termination; Ex = high-impact, free-fall 
simulated exercise; ZA = zoledronic acid treatment; HU = hindlimb unloading 
 
 
High-Impact, Free-Fall Simulated Exercise (Ex) 
Rats performed high-impact, free-fall simulated exercise through a custom-
designed drop training protocol.  Animals in groups Ex+HU and Ex+ZA+HU were 
dropped 25 times (five drops from 30 cm followed by 20 drops from 60 cm) thrice 
weekly (sessions separated by at least 48 hours) for five weeks.   Using the basic four-
finger scruff hold, Ex animals were dropped, given an 11 sec rest (shown to be an 
optimal rest period for rat bone growth) (117,118), then picked up and dropped again 
until all drops were completed.  During the rest period, the rats were held in the trainer's 
arms and lightly petted.  After 25 completed drops, which took approximately 5 minutes, 
rats were put back in their cages to resume normal cage activity for the next 48 hrs.  The 
health of the animals was assessed by project personnel and by the Comparative 
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Medicine Program (CMP) staff 2-3 times each day.  We were looking for: 1) normal 
cage activity, 2) normal ad-libitum, 3) normal gait, and 4) any signs of general distress, 
limping, or swelling.  If a rat appeared injured based on the aforementioned criteria, they 
did not perform the following session of jumps.  If the rat in question did not improve 
past the first skipped session, it was removed from the study.  We chose high-impact, 
free-fall simulated exercise based on previous findings which found this type of loading 
to be osteogenic in rats (117-119).  Results from Welch et al. concluded that free-fall 
impact from heights of 30 and 60 cm generated significant gains in CSA and BMD in 
both the ends and the shafts of forelimb bones, yet they showed only marginal gains in 
the hindlimbs (118).  According to peak vertical impact force production, the forefeet 
received over twofold higher loads than the hind feet, likely explaining the 
ineffectiveness of this type of training at the tibia and femur.  To account for this, we 
adapted our impact training by dropping the rats hind feet first, thus producing greater 
force production in the tibia and femur relative to the forefeet.  Peak ground reaction 
forces (GRF) experienced in the forelimbs and hindlimbs during Ex in a subset of 
animals were determined using a force plate (MatScan Evolution, Model 3150, Tekscan, 
Inc., South Boston, MA) and graphed using MatScan Analysis Software.    
Zoledronic Acid (ZA) Treatment 
A single 60 μg/kg body weight subcutaneous injection of zoledronic acid [2-
(imidazol-1-yl)-hydroxy-ethylidene-1,1-bisphosphonic acid, disodium salt, 4.75 hydrate] 
was administered to ZA+HU and Ex+ZA+HU groups on day 36 (one day before HU).  
On a mg/kg basis, our dose of 60 µg/kg body weight equates to a 4 mg dose 
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administered to a 67 kg human. ZA was kindly donated by Dr. Matthew Allen of Indiana 
University School of Medicine. 
Hindlimb Unloading (HU) 
HU was achieved by tail suspension as described previously (120-122).  Briefly, 
while under anesthesia, animal tail was first cleaned then allowed to dry thoroughly.  A 
thin layer of adhesive (Amazing Goop, Eclectic Products, Los Angeles, CA, USA) was 
then applied to the medial and lateral sides of the tail to secure the custom-made harness.  
A paperclip was used to attach the harness to a swivel that spans atop the suspension 
cage (18x18x18 in).  Suspension height was set to achieve a 30º head-down tilt.  HU 
animals permitted normal ambulation of the forelimbs, voluntary feeding, and ad-libitum 
drinking water.  Animal health was assessed thrice daily throughout the HU period. 
Euthanasia and Tissue Harvest  
 At each study endpoint (day 0 and day 65), animals were euthanized using a 
Ketamine/DexaDomitor (3:2) cocktail and killed by decapitation.  In HU groups, 
animals were anesthetized prior to removal from suspension to prevent load bearing on 
the hindlimbs prior to termination. At necropsy, soleus muscles were excised and wet 
masses were recorded.  Left femora, tibiae, humeri, and right proximal femora and spine 
were excised, cleaned of soft tissue, wrapped in gauze, soaked in phosphate buffered 
saline (PBS), and stored at -20 ºC. After excision and extraction of soft tissue, right 
distal femora and proximal tibiae were fixed with 10% formalin for 24 hours then stored 
in 70% EtOH at 4 ºC.  Right distal tibiae and humeri were excised, cleaned of soft tissue, 
and stored in 70% EtOH at 4 ºC.  Left tibiae were used for 3-piont bending, left femora 
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for μCT, FEA, and BioDent, right distal tibiae for cortical histomorphometry, and left 
proximal femora for ex vivo pQCT and mechanical testing.  The remaining tissues 
remain stored for future use. 
In Vivo Peripheral Quantitative Computed Tomography (pQCT) 
 At baseline, day 35, and day 65, serial in vivo pQCT scans were taken at the 
proximal tibia metaphysis (PTM, four slices distal to the growth plate) and the tibia 
diaphysis (TD, two slices at 50% of bone length, 1 mm apart) using a Stratec XCT 
Research-M device (Norland Corp., Fort Atkinson, WI), using a voxel size of 100 μm 
and a scanning bean thickness of 500 μm.  Daily calibration of the machine was 
performed with a hydroxyapatite standard cone phantom.  Stratec software (version 6.00, 
Norland Corp., For Atkinson, WI) was used to analyze scan slices at the PTM (contour 
mode 3, peel mode 4, outer threshold 0.450 g/cm3, inner threshold 0.800 g/cm3, and 
Cortmode 4, outer threshold 0.450 g/cm3, and inner threshold  -0.100 g/cm3) and at the 
TD (contour mode 1, peel mode 2, outer and inner threshold 0.650 g/cm3, and Cortmode 
2, outer threshold 0.650 g/cm3).       
 Cortical, cancellous, and total volumetric bone mineral density (vBMD), bone 
mineral content (BMC), bone cross-sectional areas (total, cortical, and marrow), and 
cortical thickness were averaged across slices at the PTM to yield a mean result. 
Similarly, values at the TD derived from the average of the two slices taken at that site.  
Cross-sectional moment of inertia (CSMI) values taken at the TD correspond to the 
neutral bending axis during three-point bend testing and are used in the calculation of 
mid-diaphysis material properties.  Using pQCT data, calculated strength indices were 
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derived.  Compressive strength index (CSI) and bending strength index (BSI) were 
determined by an approach similar to Lang et al. (49): 
(2-1)         CSI = vBMD2 x CSAmin , 
(2-2)     BSI = 
      
 
 , 
where vBMD is total volumetric BMD, CSAmin is the minimum cross-sectional area of 
the total cross-section, IX and IY are geometry-based moment of inertias, and W is the 
diameter of the equivalent circular cross-section, defined as 
(2-3)     W = 2 x √
      
 
 . 
  From manufacturer’s data, machine precision is ±9 mg/cm3 for cortical vBMD 
and ±3 mg/cm3 for cancellous vBMD.  In vivo coefficients of variation determined from 
repeat scans on six adult male rats are ±0.6% (total vBMD), ±1.6% (total BMC), ±1.9% 
(total area), and ±2.13% (cancellous vBMD).   
Ex Vivo Peripheral Quantitative Computed Tomography (pQCT) 
Following euthanasia (day 65), femoral necks were scanned using a Stratec XCT 
Research-M device (Norland Corp, Fort Atkinson, WI) and a custom-made femoral neck 
mold (used to align femoral neck with CT scan lines) as previously described (123).  
Scan speed was set at 2.5 mm/sec with a voxel resolution of 0.07 X 0.07 X 0.5 mm. 
Three adjacent scan lines were generated using a scout view scan and placed just below 
the femoral head.  Stratec software (version 6.00) was used to analyze scan slices 
(contour mode 3, peel mode 2, outer threshold 0.700 g/cm3, inner threshold 1.200 
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g/cm3). Values for total bone mineral content (BMC, mg/mm), total, trabecular, and 
cortical vBMD (mg/cm3), Ct.Th, and CSMI were averaged across all slices scanned to 
get a mean value.   
Ex Vivo Micro-Computed Tomography (μCT) 
Microarchitecture and morphology of femoral cancellous and cortical bone were 
obtained using high-resolution µCT scans (microCT40 Scanco Medical AG, 
Bruettisellen, Switzerland) with an isotropic resolution of 16 µm (70 kV, 114 µA, 300 
ms integration time).  All analyses were performed in accordance with previously 
published guidelines (55).   Scans were analyzed at the distal femur metaphysis and mid-
shaft diaphysis.  Metaphysis scans began 1.3 mm proximal to the peak of the growth 
plate and extended 5 mm proximally. Scans of the diaphysis began at 55% of the bone 
length and extended 1.6 mm distally.  Gaussian filtration parameters were σ = 1, support 
= 2 for both metaphysis and diaphysis.  A semi-automated contouring method was used 
to define the cancellous bone region.  Bone volume fraction (BV/TV, %), trabecular 
thickness (Tb.Th, mm), trabecular number (Tb.N, mm-1), trabecular separation (Tb.Sp, 
mm), connectivity density (Conn.D, 1/mm3), and structure model index (SMI) were 
assessed for cancellous bone in the metaphysis.  Diaphyseal cortical bone parameters 
include cortical thickness (Ct.Th, mm), total cross-sectional area (Tt.Ar, mm2), cortical 
bone area (Ct.Ar, mm2), bone area fraction (Ct.BA/TA, %), and polar moment of inertia 
(J, mm4).  Cancellous and cortical bone were segmented from soft tissue using a global 
threshold of 386 mg HA/cm3 and 696 mg HA/cm3, respectively.         
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Three-Point Bend Mechanical Testing 
 Mechanical properties from left tibia mid-shaft were evaluated using three-point 
bending load-to-failure testing.  Mid-shaft tibiae sites corresponded to pQCT sampling 
sites (50% of total bone length).  Just before testing, bones were brought to room 
temperature, hydrated with PBS, and measured (total length, half-length, anterioposterior 
(AP) and mediolateral (ML) surface diameters) using Absolute Digamatic calipers, 
(Mitutoyo Corp., Japan).  For testing, whole tibiae were placed lateral side down on 
custom-built metal pin (D=3 mm) supports (L=18 mm).   A quasi-static load, using a 
1,000 lb load cell (calibrated to 100 lb maximum load), was applied at a rate of 2.54 
mm/min to the medial side of the bone until fracture.  Raw data was collected at 10 Hz 
as load versus displacements curves and analyzed using Bluehill software (version 
2.14.582, Instron Bluehill) and a custom-written Matlab (version 7.12.0, The 
MathWorks, Inc.) program.  Material properties were calculated as previously mentioned 
in this chapter.  Briefly, structural properties were normalized to bone geometry at the 
mid-diaphysis tibia using pQCT derived cross-sectional moment of inertia (CSMI), 
extrinsic stiffness (k, slope of the linear portion of load-displacement curve), and  
support span distance (L= 18 mm) to obtain ultimate stress (Equation 1-3) and elastic 
modulus (Equation 1-5).   
Femoral Neck Mechanical Testing 
 Mechanical properties of the femoral neck were assessed via axial loading testing 
equipment (Instron 3345, Norwood, MA).  Right proximal femora were settled vertically 
into a fitted hole in a custom-made aluminum plate fixture (½-inch think) prior to 
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testing.  Using a 10-mm cylindrical platen, a quasi-static load was applied to the femoral 
head parallel to the axis of the shaft of the femur.  A displacement of the platen was 
maintained at 2.54 mm/min until fracture occurred.  Ultimate force was recorded and 
absorbed energy was obtained in MatLab similar to the aforementioned left tibia mid-
shaft.   
Reference Point Indentation 
Mechanical properties of the anterior diaphysis femur were analyzed using a 
cyclic microindentation instrument (BioDent 1000TM Reference Point Indentation, Active 
Life Scientific, Inc., Santa Barbara, CA) and BP2 probes.  A detailed description of 
BioDent microindentation mechanical testing can be found at (124).  Briefly, each 
microindentation consisted of an applied force of 9 N, cycled 10 times with a frequency 
of 2 Hz.  Up to four indentation measurements per bone were taken 1.5-2 mm apart in 
the femur diaphysis beginning at a location 75% of the total bone length (approximately 
10 mm proximal to the edge of the condyles).   Primary outcome variables are shown in 
Figure 14 and described further by Diez-Perez et al.(88).  
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Figure 14. Microindentation Curve.  Graph obtained with permission from (125). 
 
 
Finite Element Analysis  
Linear elastic micro-finite element analysis (µFEA) was performed on the distal 
femur metaphysis to evaluate mechanical properties using manufacturer’s software 
(Scanco Medical AG, Bassersdorf, Switzerland).  In order to create the µFEA model, all 
µCT-derived bone voxels were converted to approximately eight million equally sized 
brick elements.  Both cortical and cancellous bone were assigned an elastic modulus of 
10 GPa and Poisson’s ratio of 0.3.  A high-friction compression test in the z-direction 
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was then applied, effectively displacing all nodes located on the zmin face while holding 
all nodes in the zmax face fixed.  Outcome measurements included axial stiffness (N/mm) 
and percent load carried by the cortex.         
Dynamic Histomorphometry 
Intraperitoneal fluorochrome injections of demeclocycline (15 mg/kg body 
weight, Sigma Chemical, St. Louis, MO) and calcein (25 mg/kg body weight, Sigma 
Chemical, St. Louis, MO) were administered to capture two separate windows of bone 
formation.  First, at nine and two day days before HU, injections of demeclocycline were 
administered to produce an orange fluorochrome label.  Later, at nine and two days prior 
to termination, calcein was injected to achieve a green fluorochrome label.  After 
termination, undemineralized excised distal right tibia were dehydrated and embedded in 
methyl-methacrylate (Sigma-Aldrich M5, 590-9, St. Louis, MO).  After trimming down 
the methyl-methacrylate blocks, serial cross sections (150-200 μm thick) were cut using 
a diamond wafer low-speed saw (Buehler, Lake Bluff, IL) approximately 1 mm from the 
tibia-fibular junction.  OsteoMeasure Analysis Software, version 1.3 (OsteoMetrics, 
Atlanta, GA) was used to analyze each specimen and determine mineralizing 
surface/bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate 
(BFR = MS/BS · MAR).  Histomorphometric analyses follow the standardizations as 
defined previously (126).          
Tartrate-Resistant Acid Phosphatase 5b (TRAcP 5b)  
Saphenous vein blood draws were obtained pre- and post-HU.  Blood was 
allowed to clot for 10-15 minutes after extraction then centrifuged at 1500 rpm for 15 
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minutes.  Serum levels of TRAcP 5b were then assessed using the RatTRAP Assay 
(IDS, Fountain Hills, AZ, USA) and results were analyzed using a DTX 880 microplate 
reader (Beckman Coulter, Brea, CA, USA). Further details may be found at (82).   
Statistical Analyses  
All data are reported as means ± standard error of the mean (SE).  Data were 
evaluated for statistical relationships using SigmaPlot 12.5 (Systat Software Inc., San 
Jose, CA).  Comparisons among groups were performed using a one-factor ANOVA.  
When a significant effect was determined, pairwise comparisons of the means were 
evaluated by the Student-Newman-Keuls post hoc test.  For longitudinal pQCT 
comparisons, a repeated measure one-factor ANOVA was used to detect differences 
over time.  When a significant time effect was determined, pairwise comparisons of the 
means were evaluated by the Student-Newman-Keuls post hoc test.  Statistical 
significance was accepted at p<0.05.   
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CHAPTER III  
 
RESULTS 
 
Animals 
At baseline, animals averaged 473 ± 9.5 g with no significant differences 
between groups (Table 1).  Body mass declined (-10%) during the first two weeks of 
simulated exercise (Ex+HU, Ex+ZA+HU) before eventually stabilizing at 7% below 
baseline.  Compared to Day 35 values, HU led to a slight decrease in body mass (-3%) in 
non-exercised animals (HU, ZA+HU) and a slight increase in body mass (+4%) in 
animals previously exercised (Ex+HU, Ex+ZA+HU).  At the end of the study, CC 
animals gained 8% in body mass while all other groups ended just slightly below (-0.1 to 
-3%) baseline.  Soleus muscle mass was reduced by over 50% in all HU animals versus 
CC, with no differences between treatment groups (Table 1); this confirms the efficacy 
of the unloading treatment. 
 
 
Table 1. Effects of Ex, ZA, and HU on Body Mass and Soleus Muscle Mass 
 
 
 
 
Day CC HU ZA+HU Ex+HU Ex+ZA+HU
Body Mass (g) 0 471.8 ± 8.49 473.0 ± 11.29 472.8 ± 9.24 473.2 ± 9.31 472.8 ± 9.20
35 489.9 ± 7.82 α 487.1 ± 9.17 α 487.7 ± 8.76 α 441.3 ± 8.13 α† 435.2 ± 8.72 α†
65 508.3 ± 9.94 αβ 471.1 ± 8.56 β† 471.4 ± 11.26 β† 459.3 ± 8.61 αβ† 457.4 ± 13.16 αβ†
Soleus Mass (g) 65 0.194 ± 0.005 0.093 ± 0.004 † 0.090 ± 0.004 † 0.089 ± 0.003 † 0.095 ± 0.004 †
Values are presented as mean ± SE
α indicates significant difference from Day 0 value, p<0.05
β indicates significant difference from Day 35 value, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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High-Impact, Free-Fall Simulated Exercise 
 One animal did not complete the simulated exercise protocol (Ex+HU group) as 
he demonstrated an aversion to handling.  In the Ex+ZA+HU group, one animal did not 
wake from tail harnessing anesthesia.  All other animals responded to training and 
unloading with minimal stress.  To investigate whether there were differences in ground 
reaction forces (GRFs) experienced with this training between the different limbs, peak 
vertical GRFs were compared for the forelimbs and the hindlimbs during landing.  
Hindlimb GRFs were 69% higher than the forelimb, equating to hindlimb vertical forces 
of over 3X body weight (Figure 15).  Results from a pressure contour of the landing 
stance in all four limbs illustrate that pressure in the hindlimbs exceeded 25 N/cm2, 
whereas the forelimbs peaked at 15 N/cm2.  For the purpose of this study, higher 
pressure and force in the hindlimbs during landing is critical, as HU unloads the 
hindlimbs only, thus causing bone loss at that site.  To our knowledge, this is the first 
free-fall training protocol that has documented higher GRFs in the hindlimbs than in the 
forelimbs 
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Figure 15.  Normalized Peak Ground Reaction Forces.  Peak GRFs were normalized 
to animal body mass and are presented as mean ± SE.  * Indicates significant difference 
from forelimb (p<0.05). 
 
 
In Vivo Longitudinal Peripheral Quantitative Computed Tomography 
For longitudinal pQCT results (e.g., PTM and TD), HU-induced losses may be 
characterized in three ways: relative to baseline (Day 0), relative to Day 35, or relative to 
CC at Day 65.  In this study, we chose to use Day 35 (start of HU) as our reference 
point. That is, when Day 65 (post-HU) values are significantly different than Day 35 
values, we designate these HU-induced changes.  Similarly, effectiveness of our 
treatment regimens may be defined in several ways.  Again, we have chosen our primary 
comparison to be Day 65 versus Day 35. As a secondary reference point, comparisons 
among groups at Day 65 were made.      
Proximal Tibia Metaphysis.  Hindlimb unloading caused marked alterations in 
bone mass, density, and geometry.  HU (alone) animals experienced average losses in 
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total BMC and vBMD of 8.9% and 8.1%, respectively (Table 2).  Cancellous vBMD 
also declined with HU by 7.4%.  Both cortical cross-sectional area and cortical thickness 
were negatively impacted by HU compared to CC (-11 and -12%, respectively).  
Treatment with ZA completely prevented all HU-induced densitometric losses.  Total 
BMC and vBMD were fully protected with ZA, and actually increased relative to Day 35 
values (9.6% and 4.1%), to HU animals (19.4% and 12.8%), and to CC animals (6.5% 
and 6.8%).  Cortical and cancellous vBMD were also protected from losses, while the 
cortical compartment increased by 2.5% compared to Day 35.  Although total area was 
not altered by HU, ZA heightened it by 8.3%.  Furthermore, HU-induced cortical area 
and thickness losses were prevented with ZA.  In contrast to ZA monotherapy, simulated 
exercise alone did not induce densitometric or structural gains in the PTM.  Relative to 
Day 35, total BMC was 5.3% lower in Ex, yet it was not significantly different than CC, 
suggesting a protective effect in spite of slight decrements during HU.  Total vBMD was 
unchanged during 28 days of unloading (Ex+HU) relative to Day 35, ending 6.6% higher 
than HU animals.  Similar to ZA monotherapy, sequential treatment with Ex and ZA 
prevented losses in all measured densitometric parameters and produced gains in total 
and cortical BMC and vBMD. Ex+ZA increased total and cortical vBMD relative to Day 
35 values (5.0% and 4.6%), and to those in HU animals (13.2% and 11.8%), and in CC 
animals (7.2% and 6.5%).  Losses in cortical thickness were prevented with sequential 
Ex and ZA, ending 14.5% and 20.3% higher than Day 35 values and HU animals, 
respectively (Figure 16).                      
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Table 2. Longitudinal pQCT Results at the Proximal Tibia Metaphysis 
 
Day CC HU ZA+HU Ex+HU Ex+ZA+HU
Total BMC (mg/mm) 0 10.28 ± 0.21 10.43 ± 0.23 10.08 ± 0.17 10.80 ± 0.18 #† 10.79 ± 0.30
35 10.34 ± 0.18 10.51 ± 0.19 10.43 ± 0.16 10.49 ± 0.18 10.48 ± 0.20
65 10.73 ± 0.24 αβ 9.57 ± 0.15 αβ† 11.43 ± 0.23 αβ#† 9.93 ± 0.22 αβ 11.13 ± 0.27 β#†
Cortical BMC (mg/mm) 0 8.10 ± 0.15 8.06 ± 0.11 8.17 ± 0.18 8.42 ± 0.15 8.29 ± 0.24
35 8.19 ± 0.18 8.18 ± 0.13 8.53 ± 0.17 α 8.40 ± 0.19 8.28 ± 0.20
65 8.47 ± 0.17 αβ 7.50 ± 0.18 αβ 9.34 ± 0.20 αβ# 7.99 ± 0.18 8.90 ± 0.18 αβ
Cancellous BMC (mg/mm) 0 2.18 ± 0.13 2.37 ± 0.17 1.91 ± 0.13 # 2.37 ± 0.13 2.50 ± 0.15
35 2.16 ± 0.14 2.33 ± 0.17 1.90 ± 0.15 2.09 ± 0.20 2.20 ± 0.09
65 2.26 ± 0.10 2.07 ± 0.13 2.08 ± 0.18 1.94 ± 0.16 α 2.23 ± 0.17
Total vBMD (mg/cm3) 0 586.59 ± 8.62 597.24 ± 10.32 589.66 ± 7.72 597.88 ± 6.79 593.98 ± 8.64
35 574.27 ± 11.16 587.55 ± 9.81 585.21 ± 9.92 597.07 ± 15.95 582.05 ± 7.85
65 570.40 ± 7.80 540.12 ± 14.22 αβ 609.26 ± 8.29 αβ#† 575.59 ± 14.23 # 611.28 ± 8.78 β#†
Cortical vBMD (mg/cm3) 0 1054.6 ± 6.9 1052.9 ± 8.4 1061.6 ± 7.9 1053.7 ± 6.2 1054.1 ± 6.7
35 1053.1 ± 9.8 1060.5 ± 8.0 1067.5 ± 8.5 1072.3 ± 13.5 1067.6 ± 5.5
65 1055.8 ± 5.5 1049.0 ± 12.1 1093.9 ± 6.4 αβ#† 1076.1 ± 10.5 1098.7 ± 6.1 αβ#†
Cancellous vBMD (mg/cm3) 0 215.74 ± 7.76 233.67 ± 11.87 198.15 ± 10.34 # 230.85 ± 11.06 235.46 ± 7.73
35 203.92 ± 7.94 223.33 ± 10.03 187.21 ± 11.12 # 205.16 ± 9.79 α 210.87 ± 6.27 α
65 204.16 ± 6.33 189.45 ± 7.40 αβ 197.60 ± 13.25 189.90 ± 10.53 α 213.13 ± 9.05 α#
Total Area (mm2) 0 17.58 ± 0.38 17.55 ± 0.45 17.15 ± 0.27 18.09 ± 0.36 18.25 ± 0.53
35 17.32 ± 0.30 17.65 ± 0.43 17.37 ± 0.33 17.49 ± 0.52 17.71 ± 0.464
65 18.86 ± 0.38 αβ 17.88 ± 0.44 18.82 ± 0.39 αβ 17.37 ± 0.50 18.28 ± 0.55
Cortical Area (mm2) 0 7.68 ± 0.13 7.67 ± 0.11 7.70 ± 0.14 8.00 ± 0.14 7.88 ± 0.21
35 7.77 ± 0.13 7.72 ± 0.12 7.99 ± 0.13 α 7.84 ± 0.15 7.75 ± 0.17
65 8.03 ± 0.15 αβ 7.15 ± 0.13 αβ† 8.55 ± 0..17 αβ#† 7.43 ± 0.14 αβ† 8.11 ± 0.17 αβ#
Marrow Area (mm2) 0 9.90 ± 0.31 9.88 ± 0.37 9.44 ± 0.23 10.09 ± 0.27 10.37 ± 0.41
35 10.33 ± 0.39 10.26 ± 0.40 9.93 ± 0.33 9.92 ± 0.62 10.29 ± 0.26
65 10.84 ± 0.28 α 10.73 ± 0.43 10.27 ± 0.30 9.95 ± 0.47 10.18 ± 0.44
Cortical Thickness (mm) 0 0.66 ± 0.03 0.61 ± 0.03 0.61 ± 0.02 0.65 ± 0.04 0.66 ± 0.01
35 0.63 ± 0.04 0.63 ± 0.03 0.68 ± 0.02 α 0.67 ± 0.03 0.62 ± 0.03
65 0.67 ± 0.02 0.59 ± 0.02 † 0.73 ± 0.01 αβ#† 0.64 ± 0.02 0.71 ± 0.02 β#
CSMI (mm4) 0 31.63 ± 1.27 31.85 ± 1.41 30.72 ± 0.95 33.70 ± 1.18 34.27 ± 1.80
35 33.58 ± 1.43 33.22 ± 1.52 33.36 ± 1.28 32.88 ± 2.15 33.55 ± 1.18
65 36.54 ± 1.40 α 32.97 ± 1.42 36.44 ± 1.37 α 32.03 ± 1.54 34.56 ± 1.87
Values are presented as mean ± SE
α indicates significant difference from Day 0 value, p<0.05
β indicates significant difference from Day 35 value, p<0.05
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Figure 16. Longitudinal Densitometric/Geometric Changes.  Values assessed at the 
Proximal Tibia Metaphysis. (A) Total BMC, (B) Total vBMD, (C) Cortical vBMD, (D) 
Cancellous vBMD, (E) Total Area, and (F) Cortical Thickness.  Light grey bars 
represent % change values from Day 0 to Day 35.  Dark grey bars represent % change 
values from Day 35 to Day 65.  Values are presented as mean ± SE. α Indicates 
significant difference from Day 0 (p<0.05). β Indicates significant difference from Day 
35 to Day 65 (p<0.05).  # Indicates significant difference from HU (p<0.05). † Indicates 
significant difference from CC (p<0.05). 
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Mid-Diaphysis Tibia.  Hindlimb unloading did not result in densitometric or 
calculated strength losses in tibia diaphyseal bone.  Cortical vBMD actually increased 
slightly during 28 days of unloading by an average of 0.82%.  Despite the slight change 
in cortical vBMD during HU, mid-shaft pQCT values were similar to CC at the end of 
the study in all groups at every time point.     
 
 
Table 3. Longitudinal pQCT Results at the Tibia Diaphysis 
 
 
 
Day CC HU ZA+HU Ex+HU Ex+ZA+HU
Cortical BMC (mg/mm) 0 8.62 ± 0.14 8.24 ± 0.16 7.89 ± 0.16 8.28 ± 0.13 8.18 ± 0.14
35 8.64 ± 0.12 α 8.76 ± 0.18 α 8.29 ± 0.15 α 8.64 ± 0.13 α 8.77 ± 0.19 α
65 8.83 ± 0.12 αβ 8.87 ± 0.15 α 8.45 ± 0.17 α 8.73 ± 0.13 α 8.72 ± 0.17 α
Cortical vBMD (mg/cm3) 0 1329 ± 4.2 1330 ± 4.1 1327 ± 3.1 1322 ± 2.2 1327 ± 5.1
35 1339 ± 4.9 1334 ± 1.9 1336 ± 4.9 α 1340 ± 6.1 α 1335 ± 2.7
65 1351 ± 3.3 α 1345 ± 3.2 αβ 1348 ± 4.5 αβ 1355 ± 4.8 αβ 1350 ± 2.9 αβ
Corticl Area (mm2) 0 6.22 ± 0.11 6.20 ± 0.13 5.95 ± 0.12 6.26 ± 0.11 6.17 ± 0.11
35 6.45 ± 0.09 α 6.57 ± 0.14 α 6.21 ± 0.11 α 6.45 ± 0.09 α 6.57 ± 0.14 α
65 6.54 ± 0.09 α 6.59 ± 0.11 α 6.27 ± 0.13 α 6.44 ± 0.09 α 6.46 ± 0.13 α
Total Area (mm2) 0 8.89 ± 0.16 8.96 ± 0.22 8.61 ± 0.13 9.05 ± 0.17 8.93 ± 0.22
35 9.19 ± 0.17 9.59 ± 0.19 α 9.06 ± 0.17 α 9.31 ± 0.21 9.54 ± 0.23 α
65 9.43 ± 0.16 α 9.55 ± 0.17 α 9.04 ± 0.17 α 9.24 ± 0.21 9.31 ± 0.25 α
Cortical Thickness (mm) 0 0.79 ± 0.012 0.75 ± 0.035 0.76 ± 0.01 0.71 ± 0.044 0.71 ± 0.046
35 0.79 ± 0.009 0.71 ± 0.045 0.76 ± 0.012 0.77 ± 0.013 0.79 ± 0.013
65 0.80 ± 0.004 0.80 ± 0.012 0.75 ± 0.030 0.80 ± 0.016 0.79 ± 0.012
CSMI (mm4) 0 6.21 ± 0.22 6.30 ± 0.31 5.80 ± 0.21 6.47 ± 0.25 6.25 ± 0.27
35 6.69 ± 0.24 7.25 ± 0.33 α 6.46 ± 0.24 α 6.88 ± 0.31 7.22 ± 0.32 α
65 6.98 ± 0.22 α 7.18 ± 0.25 α 6.44 ± 0.25 α 6.78 ± 0.29 6.86 ± 0.32 α
SSI (mm3) 0 6.28 ± 0.16 6.28 ± 0.20 5.87 ± 0.14 6.23 ± 0.15 6.17 ± 0.20
35 6.63 ± 0.15 α 6.88 ± 0.19 α 6.31 ± 0.15 α 6.60 ± 0.15 α 6.80 ± 0.25 α
65 6.88 ± 0.15 αβ 6.94 ± 0.16 α 6.44 ± 0.17 α 6.60 ± 0.16 α 6.69 ± 0.25 α
BSI (mm3) 0 3.68 ± 0.10 3.71 ± 0.14 3.50 ± 0.10 3.80 ± 0.11 3.70 ± 0.12
35 3.90 ± 0.11 4.14 ± 0.14 3.79 ± 0.10 α 3.98 ± 0.13 4.13 ± 0.13 α
65 4.02 ± 0.1 α 4.11 ± 0.11 α 3.78 ± 0.11 α 3.94 ± 0.13 3.97 ± 0.14 αβ
Values are presented as mean ± SE
α indicates significant difference from Day 0 value, p<0.05
β indicates significant difference from Day 35 value, p<0.05
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Ex Vivo Longitudinal Peripheral Quantitative Computed Tomography 
Femoral Neck.  Relative to CC, HU caused significant reductions in total BMC 
(-11.0%), total and cancellous vBMD (-5.6 and -13.7%), cortical area (-9.8%), and CSI 
(-16.1) at the femoral neck (FN) (Table 4).  Alone, Ex and ZA mitigated losses in total 
BMC and cortical area, and completely prevented declines in total and cancellous vBMD 
and CSI.  When applied in sequence, Ex and ZA completely prevented all HU-induced 
decrements in bone densitometry.  Sequential therapy did not, however, appear to 
provide additive benefits in the femoral neck.  That is, Ex+ZA+HU values were not 
significantly higher than ZA+HU or Ex+HU in any FN variables measured, although 
combined treatment did protect against BSI, SSI, and BMC losses whereas monotherapy 
did not.   
 
 
Table 4.  Femoral Neck Imaging Results by pQCT 
 
CC HU ZA+HU Ex+HU Ex+ZA+HU
Total BMC (mg/mm) 5.53 ± 0.17 4.92 ± 0.098 † 5.20 ± 0.10 5.26 ± 0.11 5.63 ± 0.15 #
Cortical BMC (mg/mm) 3.71 ± 0.10 3.36 ± 0.10 † 3.62 ± 0.08 3.64 ± 0.10 3.81 ± 0.09 #
Cancellous BMC (mg/mm) 1.83 ± 0.12 1.54 ± 0.10 † 1.58 ± 0.07 1.62 ± 0.08 1.82 ± 0.11 #
Total vBMD (mg/cm3) 1088 ± 17 1027 ± 24 † 1086 ± 18 # 1096 ± 14 # 1112 ± 14 #
Cortical vBMD (mg/cm3) 1450 ± 8 1461 ± 6 1456 ± 5 1452 ± 5 1457 ± 4
Cancellous vBMD (mg/cm3) 715.5 ± 22.4 617.3 ± 13.2 † 682.4 ± 20.7 # 704.1 ± 26.1 # 739.4 ± 15.0 #
Total Area (mm2) 5.10 ± 0.17 4.83 ± 0.16 4.81 ± 0.13 4.80 ± 0.06 5.08 ± 0.17
Cortical Area (mm2) 2.56 ± 0.08 2.31 ± 0.06 † 2.48 ± 0.06 2.51 ± 0.07 2.61 ± 0.06 #
Marrow Area (mm2) 2.54 ± 0.15 2.52 ± 0.18 2.33 ± 0.12 2.29 ± 0.06 2.46 ± 0.15
Cortical Thickness (mm) 0.41 ± 0.050 0.40 ± 0.028 0.45 ± 0.019 0.46 ± 0.013 # 0.47 ± 0.013 #
BSI (mm3) 1.76 ± 0.08 1.61 ± 0.05 1.79 ± 0.11 1.71 ± 0.04 1.85 ± 0.07 #
CSI (mg2/mm4) 6.02 ± 0.21 5.05 ± 0.14 † 5.64 ± 0.13 # 5.77 ± 0.18 # 6.25 ± 0.15 #
SSI (mm3) 2.62 ± 0.11 2.38 ± 0.11 2.56 ± 0.09 2.60 ± 0.07 2.80 ± 0.11 #
Values are presented as mean ± SE
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Microarchitecture Assessed by Micro-Computed Tomography 
Distal Femur Metaphysis. HU resulted in marked alterations in cancellous 
microarchitecture. Compared to CC, HU rats had lower BV/TV (Figure 17) and Tb.Th, 
and higher SMI in the distal femur metaphysis (-24%, -15%, and+23%, respectively) 
(Table 5).  Treatment with ZA completely prevented disuse-induced losses in BV/TV 
(Figure 17) and Tb.Th (Figure 18) and inhibited increases in SMI.  Although Conn.D 
was not reduced with HU, ZA+HU animals ended the study with 20% higher Conn.D 
than CC.  Simulated exercise alone prevented losses with HU in Tb.Th (Figure 18) and 
increases in SMI but had no effect on BV/TV.  Improvements in BV/TV, Conn.D, and 
SMI were greatest in rats treated with both ZA and Ex.  BV/TV in Ex+ZA+HU animals, 
for example, was 60% greater than HU and 21% higher than CC.  Total bone volume 
(BV) in the distal femur metaphysis was also reduced with HU (-12.2) compared to CC.  
Treatment with either ZA or Ex alone mitigated total BV losses, while the combined 
therapy (Ex+ZA) yielded improvements to levels above CC.   
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Table 5. Cancellous and Cortical Microarchitecture and Morphology Assessed by µCT 
at the Distal Femur Metaphysis and Femur Diaphysis.    
 
 
 
 
 
Figure 17. Relative Bone Volume at the Distal Femur.  Images expressed (A) 
graphically and (B) visually. Values are group mean ± standard error of the mean.  †vs. 
CC (p<0.05); #vs. HU (p<0.05). 
 
 
 
CC HU ZA+HU Ex+HU Ex+ZA+HU
Distal Cancellous
BV/TV (%) 0.20 ± 0.01 0.15 ± 0.008 † 0.22 ± 0.02 # 0.19 ± 0.01 0.24 ± 0.02 †#
Tb.Th (mm) 0.092 ± 0.001 0.078 ± 0.001 † 0.094 ±0.002 # 0.087 ± 0.002 # 0.097 ± 0.003 #
Tb.Sp (mm) 0.35 ± 0.02 0.33 ± 0.02 0.37 ± 0.03 0.35 ± 0.02 0.33 ± 0.02
Tb.N (mm-1) 2.85 ± 0.13 2.96 ± 0.11 2.83 ± 0.16 2.85 ± 0.15 3.03 ± 0.13
ConnD (mm-3) 47.0 ± 3.1 42.9 ± 3.7 56.2 ± 4.9 # 49.0 ± 4.5 56.4 ± 3.9 †#
SMI 1.81 ± 0.08 2.24 ± 0.09 † 1.66 ± 0.14 # 1.86 ± 0.09 # 1.39 ± 0.13 †#
Diaphysis Cortical
vBMD (mg/cm3) 1203.7 ± 3.6 1220.2 ± 2.5 1228.5 ± 1.8 1224.8 ± 0.5 1225.3 ± 1.8
Ct. BA/TA (%) 61.2 ± 1.1 61.2 ± 0.4 61.1 ± 0.4 59.6 ± 1.1 59.4 ± 0.8
Ct.Por (%) 0.081 ± 0.004 0.066 ± 0.005 0.087 ± 0.010 0.071 ± 0.006 0.076 ± 0.005
Ct. Th (mm) 0.79 ± 0.01 0.79 ± 0.01 0.79 ± 0.01 0.77 ± 0.005 0.78 ± 0.01
pMOI (mm4) 26.9 ± 1.0 25.6 ± 0.6 25.6 ± 0.7 26.4 ± 0.9 28.4 ± 1.4
Values are presented as mean ± SE
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Figure 18. Trabecular Thickness at the Distal Femur Metaphysis. Images expressed 
(A) graphically and (B) thickness color map. Values are group mean ± standard error of 
the mean.  †vs. CC (p<0.05); #vs. HU (p<0.05). 
 
 
Mid-Diaphysis Femur. Unlike at the distal femur metaphysis, none of the µCT 
parameters measured at the femoral mid-shaft diaphysis were significantly different 
across groups (Table 4). 
Femoral Neck Biomechanical Findings 
The ultimate force in axial mechanical testing of the femoral neck in HU animals 
was 20% lower than CC counterparts (Figure 19A).  Compared to total vBMD in the 
femoral neck (-6% loss versus CC), losses in ultimate force were nearly fourfold higher, 
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suggesting an underestimation of bone strength by this measure of bone mass.  Similarly, 
energy to ultimate force was drastically reduced with HU (-35%) (Figure 19B).  Both 
monotherapy with either Ex or ZA, as well as sequential treatment, prevented the 
aforementioned disuse-induced strength losses.  
 
 
 
Figure 19. Femoral Neck Biomechanical Testing. (A) Ultimate Force and (B) Energy 
to Ultimate Force.  Values are group mean ± standard error of the mean.  †vs. CC 
(p<0.05); #vs. HU (p<0.05). 
 
 
Tibia Mechanical Properties 
 With the exception of ultimate stress, which was reduced by 13.4% with HU and 
recovered with treatment, mechanical properties of the mid-tibia diaphysis were 
generally unaffected by loading status or drug treatment (Table 6). 
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Table 6. Three-Point Bending Biomechanical Testing at the Tibia Diaphysis 
 
 
 
Finite Element Derived Estimates of Strength 
Compressive stiffness of the combined cortical and cancellous compartments at 
the distal femur metaphysis was significantly lower in HU (-13%) versus CC animals 
(Figure 20A).  Interestingly, HU-induced reductions in stiffness are 1.7-fold greater than 
respective losses in total vBMD (-8%), suggesting an underestimation of mechanical 
properties by total vBMD. Monotherapy with either ZA or Ex improved stiffness back to 
CC values.  Combination therapy, however, heightened stiffness beyond both HU and 
CC animals (34% and 16%, respectively).  Distribution of load sharing between cortical 
and cancellous bone also was altered with HU.  Compared to CC, HU animals 
experienced 4% higher loads in the cortex (Figure 20B).  Alone and in combination, ZA 
and Ex protected against unfavorable alterations in load sharing.   
CC HU ZA+HU Ex+HU Ex+ZA+HU
Stiffness (N/mm) 367.1 ± 15.6 359.7 ± 14.2 333.8 ± 16.5 343.8 ± 18.7 374.7 ± 16.6
Ultimate Force (N) 140.7 ± 3.3 134.0 ± 3.4 134 ± 4.0 143 ± 2.0 136.8 ± 3.9
Energy to Ultimate Force (mJ) 50.7 ± 3.2 44.3 ± 3.1 43.3 ± 2.6 49.4 ± 3.4 47.4 ± 3.9
Post-Yield Displacement (mm) 0.46 ± 0.054 0.52 ± 0.055 0.62 ± 0.08 0.51 ± 0.078 0.54 ± 0.066
Ultimate Stress (MPa) 178.2 ± 4.8 154.4 ± 7.4 † 181.1 ± 7.9 # 186.6 ± 7.1 # 171.3 ± 6.8
Elastic Modulus (GPa) 6.46 ± 0.33 6.10 ± 0.17 6.40 ± 0.39 6.31 ± 0.35 6.78 ± 0.39
Values are presented as mean ± SE
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Figure 20. Finite Element Analysis-Derived Mechanical Properties. (A) Stiffness, 
(B) %Cortex Load, and (C) Cortical-cancellous load sharing color map depicted as von 
Mises stress distribution.  Values are group mean ± standard error of the mean.  †vs. CC 
(p<0.05); #vs. HU (p<0.05).  
 
 
Material Properties from Reference Point Indentation  
No significant differences in reference point indentation were observed among 
groups.  IDI, ID 1st, TID, nor US was found to be significantly altered with HU or Ex 
and ZA treatment options (Table 7).  Figure 21 illustrates a high resolution µCT image 
taken post-RPI testing with indentation sites indicated.     
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Table 7. Reference Point Indentation Results at the Femur Diaphysis 
 
 
 
 
 
Figure 21. Microindentation Anatomical Sites.  µCT illustration of three 
representative RPI indentations along the femur diaphysis spaced 1-2 mm apart. 
 
 
CC HU ZA+HU Ex+HU Ex+ZA+HU
IDI (µm) 7.92 ± 0.15 7.88 ± 0.15 8.17 ± 0.17 7.96 ± 0.16 8.36 ± 0.19
ID 1st  (µm) 59.3 ± 0.87 59.5 ± 1.15 58.0 ± 0.76 58.2 ± 1.77 59.4 ± 0.81
TID (µm) 63.7 ± 0.91 63.8 ± 1.05 63.0 ± 0.81 62.6 ± 1.49 64.3 ± 0.77
US (N/µm) 0.60 ± 0.015 0.63 ± 0.018 0.62 ± 0.020 0.64 ± 0.018 0.60 ± 0.014
Values are presented as mean ± SE
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
 65 
 
Bone Formation Assessed by Dynamic Histomorphometry 
 Longitudinal assessment of cortical histomorphometry along the periosteal 
surface via calcein double fluorochrome labels indicate that HU, regardless of treatment 
status, significantly reduced MS/BS, MAR, and BFR compared to controls (Table 8).  In 
Ex+ZA+HU animals, MS/BS (% change, Figure 22) was significantly higher than HU, 
while MAR (% change) was significantly lower.  Representative images of our two sets 
of double labels in CC and HU sections are depicted in Figure 23.  When samples were 
missing double labeling, as in the HU group in Figure 23, a minimum MAR of 0.3 
µm/day was assigned.  Bone formation rate was unaffected by either simulated exercise 
(as indicated by demeclocycline) or ZA (as indicated by calcein), as percent change 
differences between HU groups were not statistically different.  An alternative method 
for determining BFR when double label is missing is to designate MAR as “missing 
data” rather than setting it to 0.3 µm/day.  When calculated this way, BFR in CC animals 
significantly increased (+75%, compared to +63% as previously calculated) while all 
HU animals significantly decreased by an average of -90%.  No labels were found on 
endocortical surfaces.  
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Table 8. Periosteal Fluorochrome Label Results 
 
 
 
 
    
Figure 22. Longitudinal Dynamic Histomorphometry. Data assessed along periosteal 
cortical bone. (A) MS/BS, (B) MAR, and (C) BFR. Values are group mean percent 
change (calculated by the percent difference between values obtained via calcein and 
demeclocycline) ± standard error of the mean.  †vs. CC (p<0.05); #vs. HU (p<0.05). 
  
CC HU ZA+HU Ex+HU Ex+ZA+HU
End of Ex period
Double label on periosteum (n) 10/11 11/11 11/11 3/9 10/12
MS/BS (%) 14.20 ± 2.50 16.99 ± 2.85 15.58 ± 1.93 11.94 ± 3.63 # 14.0 ± 3.07
MAR (µm/day) 7.11 ± 2.59 9.00 ± 2.52 5.28 ± 1.13 6.24 ± 3.29 4.33 ± 1.21 #
BFR (um3/µm2/day) 150.6 ± 77.5 179.9 ± 77.7 111.4 ± 30.3 164.8 ± 100.7 101.4 ± 40.3 #
End of HU period
Double label on periosteum (n) 9/11 2/11 3/11 0/9 6/12
MS/BS (%) 16.87 ± 3.34 3.59 ± 1.46 † 2.60 ± 0.69 † 1.35 ± 0.25 † 3.14 ± 0.54 †
MAR (µm/day) 9.01 ± 3.25 1.08 ± 0.74 † 1.08 ± 0.49 † 0.30 ± 0.04 † 0.32 ± 0.04 †
BFR (um3/µm2/day) 169.8 ± 101.0 10.50 ± 8.98 † 6.75 ± 4.35 † 0.39 ± 0.08 † 0.96 ± 0.21 †
Values are presented as mean ± SE
# indicates significant difference from HU at same timepoint, p<0.05
† indicates significant difference from CC at same timepoint, p<0.05
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Figure 23. Representative Images of Periosteal Labeling.  (A) CC animal and (B) HU 
animal. 
 
 
Systemic Resorption: Tartrate-Resistant Acid Phosphatase 5b (TRAcP 5b)  
 At the end of the study, HU serum TRAcP 5b levels, which provide a systemic-
level indicator of active osteoclasts, were 61% higher than in CC animals (Figure 24).  
ZA administered with and without simulated exercise reduced TRAcP 5b by 87 and 
77%, respectively, compared to HU, and 80 and 39%, respectively, compared to CC.  Ex 
alone did not affect TRAcP 5b, as levels were not significantly different than HU or CC 
at day 65 (Figure 24) or at day 35 (data not shown).   
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Figure 24. Serum TRAcP 5b Levels at Day 65.  Values are group mean ± standard 
error of the mean.  †vs. CC (p<0.05); #vs. HU (p<0.05). 
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CHAPTER IV  
 
DISCUSSION 
 
Densitometry, Microarchitecture, and Morphology 
The salient densitometric, microarchitectural, and morphological findings of this 
study were threefold.  First, we found that a single injection of ZA (60 µg/kg body 
weight) administered just prior to 28 days of unloading protected against mass, density, 
and geometry alterations in the PTM, distal femur metaphysis (DFM), and FN of adult 
rats.  Second, high-impact, free-fall simulated exercise, characterized by thrice weekly 
drops (25X/session) had a similar effect relative to ZA treatment.  Thirdly, when applied 
in sequence, Ex and ZA completely prevented disuse-induced bone decrements at the 
PTM and FN and was superior to either treatment alone at the DFM.    
Bisphosphonates are currently the frontline class of drugs used to treat 
osteoporosis and other diseases related to increased bone resorption.  Overwhelming 
evidence demonstrates the efficacy of bisphosphonates in reducing bone loss and 
fracture risk.  A variety of bisphosphonates are available for use, each being 
characterized by their speed and duration of action as well as their effects on fracture 
reduction (37).  ZA, for example, the most potent of all bisphosphonates, has an 
extremely high binding affinity for hydroxyapatite and is a major inhibitor of osteoclast-
mediated bone resorption (127).  Although bisphosphonates primary action is the 
inhibition of bone resorption, it is generally agreed that bisphosphonate-induced bone 
gain, rather than simply a suppression of loss, is the result of a reduction in remodeling 
space by the re-filling of resorption cavities and an increase in secondary mineralization 
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(128).  In a rodent study, prophylactic ZA treatment (20 µg/kg body weight) completely 
prevented OVX-induced alterations in bone microarchitecture (129).   
We cannot strictly compare our results to the latter studies, as our rats were male, 
were given a different dose of ZA (60 µg/kg body weight), and, most notably, were 
subjected to disuse rather than to gonadectomy.  However, we also saw complete mass, 
density, and microarchitectural protection with a single dose of ZA. Our dose of 60 
µg/kg body weight was chosen because it falls between the generally accepted low- and 
high-doses used in animal studies and is comparable to the clinical dose of a 4 mg 
infusion in humans.  Furthermore, since bone loss with disuse occurs far more rapidly 
than with estrogen deficiency, we conjectured that typical low-dose OVX treatment may 
not suffice for our purposes.  To our knowledge, this is the first study to investigate the 
efficacy of ZA, at any dose, in HU rats.  ZA has been used, however, in mice subjected 
to two weeks of HU (111).  Conn.D and BV/TV were both significantly reduced during 
HU in PBS-treated animals versus loaded controls.  A single injection of 45 µg/kg body 
weight drastically increased Conn.D and BV/TV and blunted declines in cortical area 
and thickness.  Similar to Lloyd et al.(111), the present study demonstrated that ZA 
therapy prevented unloading-induced alterations in architecture and structure.              
Although ZA did improve densitometric and geometric properties beyond aging 
controls, it is not considered an anabolic therapy.  Exercise, on the other hand, is 
considered anabolic, as it has been shown to be an osteogenic stimulus in both normal- 
and under-loaded conditions.  Eight weeks of resistance exercise (1 hour of jumping 
every other day) significantly improves L5 and mid-diaphysis femur BMD in normally 
 71 
 
loaded young rats (130).  Exercise countermeasures applied during and after periods of 
disuse have also been investigated.  Simulated resistance training (SRT) performed 
during 28 days of HU abolishes disuse-induced deterioration of total, cortical, and 
cancellous bone mass, density, and area (78).  When executed after unloading, 10 jumps 
per day for two weeks restores cancellous architecture back to baseline levels (71).  Our 
study is unusual in that it employed simulated exercise prior to, rather than during or 
after, a period of unloading.  We conjectured that, by introducing exercise before HU, 
animals would initiate the unloading period with stronger bones than non-exercising 
counterparts and would be better protected from skeletal degradation.   
According to our peak ground reaction force and pressure contour data, the 
hindlimbs of our rats during simulated exercise were loaded nearly twice that of the 
forelimbs, producing higher pressures at that site.  Even with these higher loads, 
however, we failed to show significant gains in bone mass, density, and geometry after 
35 days of drop training.  These shortcomings are likely the result of declines in body 
weight in our Ex animals.  According to Shapses et al., for every 10% drop in body 
mass, BMD declines by approximately 1% (131).  When normalized to body weight 
(data not shown), however, total BMD was significantly higher in Ex versus non-Ex 
animals.  Regardless of changes in body weight throughout the study, HU-induced bone 
loss in the PTM, FM, and DFM was mitigated in Ex animals.     
While it was an attractive hypothesis to sequentially administer an osteogenic 
stimulus with an anti-resorptive bisphosphonate, this intervention did not produce 
additive benefits in all bone sites assessed.  At the PTM and FN, for example, Ex+ZA 
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values were not significantly higher than either intervention alone.  However, at the 
DFM, improvements in BV/TV, Conn.D, and SMI were greatest when Ex and ZA were 
applied in sequence.  This site-specific response may be explained by different strain 
environments among bone sites.  Although we do not have strain gauge data to support 
this claim, it is possible that deformations at the DFM produced a more favorable 
environment for osteogenesis.  An alternate explanation may be in the imaging technique 
used.  It is possible that the higher sensitivity of the µCT was capable of capturing subtle 
changes in microarchitecture at the DFM whereas pQCT was unable to detect these 
differences at the FN and PTM. 
  Comparisons of the present study with others using combination 
bisphosphonate and exercise treatments to counter bone loss should be made with 
caution.  To begin, this is the first study to sequentially pre-treat HU rats with simulated 
exercise and ZA. Furthermore, the use of dissimilar bisphosphonates, exercise type, 
age/sex of animals, and timing of treatment make direct comparisons across studies 
hazardous.  Nevertheless, it is important to consider these studies as the exercise-
bisphosphonate interaction remains unclear.  Stadelmann et al. demonstrated that 
singular treatments with 1) axial loading with no muscle contractions  or 2) ZA therapy 
increased cortical bone area and perimeter, respectively, while loading-ZA combination 
therapy was additive in most sites (132).  In areas of high strain measured at the tibia 
mid-shaft, however, the combined effect was significantly lower than the sum of the 
effects, suggesting an upper limit of mechanical loading benefits when administered 
with ZA.  Although we do not have strain data, it is possible that during landing our 
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animals experienced mechanical strains in the PTM and FN beyond the aforementioned 
upper limit, thus preventing an additive response at those sites.  Although we did not 
show greater rescue from HU-induced bone loss at the PTM and FN with sequential 
countermeasures compared to monotherapy, DFM bone mass was highest in Ex+ZA 
animals at the end of the study, suggesting greater protection from disuse than either 
intervention alone.  This site-specific reaction has been shown by others, where regional 
differences in the response of the tibia and femur to treadmill running and the 
bisphosphonate etidronate exist (133).     
 A few clinical studies have also investigated the combined role of exercise and 
bisphosphonates, yet none have demonstrated combined benefits beyond either treatment 
alone (134-136).  Chilibeck et al. performed a randomized trial investigating the 
combined effect of moderate intensity resistance training (three times per week for 45 
minutes) and etidronate (administered for 12 months at a dose of 400 mg/day over 14 
days) on bone health in postmenopausal women (134).  Etidronate significantly 
improved whole body and lumbar spine BMD compared to placebo treated controls, yet 
no interactive or additive benefits where found in patients also exercising. Similar 
findings were shown by Uusi-Rasi et al. in a study of 164 postmenopausal women taking 
a daily dose of alendronate (5 mg) and physical exercise (136).  Daily activity consisted 
of progressive jump exercises for 20 minutes plus 15 minutes of stretching.  Alone, 
alendronate proved an effective countermeasure as it improved bone mass in the lumbar 
spine and femoral neck.  While exercise heightened participants’ muscular performance 
and balance, it had no effect on bone mass.  Taken together, exercise did not enhance the 
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beneficial effects that were gained by alendronate therapy.  The lack of interaction 
between exercise and bisphosphonates in the former two studies may be explained by the 
timing of interventions.  Since bisphosphonates inherently reduce bone turnover, it is 
likely that the anabolic potential of exercise was blunted by the bisphosphonate, 
disallowing exercise-induced gains in bone mass.  In a postmenopausal population 
similar in age and health status to those investigated by Uusi-Rasi et al., six months of 
high-impact jump exercise training significantly increased BMD in the lumbar spine and 
femoral neck compared to non-exercising controls (137).  Thus, it is possible to accrue 
bone through exercise in osteopenia/osteoporosis patients past menopause.  Results from 
our study advocate for clinical research investigating the sequential rather than 
concurrent use of exercise and bisphosphonates in patients suffering from low bone 
mass.     
 In this study, we focused on countermeasures to disuse-induced bone loss 
incurred via 28 days of hindlimb unloading in adult male rats.  HU caused marked 
alterations in bone mass, density, and geometry at the PTM, FN, and DFM that was 
partially recovered with high-impact, free-fall mechanical loading and fully recovered 
with 60 µg/kg body weight of ZA.  When administered sequentially, we saw a site-
specific reaction to recovery.  Whereas the PTM and FN did not experience additive 
benefits with Ex+ZA, microarchitecture values were highest at the DFM when exercise 
preceded ZA.           
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Biomechanical Properties 
The most important biomechanics finding of this study was that our sequential 
prescription of high-impact mechanical loading followed by ZA protected against 
disuse-induced mechanical strength losses in adult rats more effectively than either 
treatment alone.  HU caused marked reductions in mechanical properties at the FN and 
DFM that were partially rescued with monotherapy of Ex and ZA and completed 
prevented with the combination.  Although we did not demonstrate HU- or treatment-
induced strength changes at the femur diaphysis, these data are in accordance with µCT 
results at that site. 
    As demonstrated here, bone mass (quantity) was decreased with HU and 
salvaged with Ex and/or ZA treatment.  According to the National Institute of Health, 
however, bone strength, and ultimately its susceptibility to fracture, is a function of both 
bone quantity and quality (138).  While bone mass is intuitively understood and readily 
measurable using standard imaging techniques, bone quality is much more elusive and 
remains to be uniquely defined.  One may consider bone quality to be a compound term 
which incorporates all aspects of bone strength apart from bone mass.  For example, 
Felsenberg et al. developed the “bone quality framework,” which explains bone quality 
as an umbrella term characterized by both structural properties (e.g., geometry and 
microarchitecture) and material properties (e.g., degree of mineralization and 
microdamage) (139).  We have shown that bone geometry (PTM, cortical thickness) and 
microarchitecture (DFM, BV/TV) were negatively impacted by unloading and positively 
influenced by treatment.   Here, we discuss bone material properties as determined by 
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estimates (finite element modeling) and by direct measurements (RPI, FN testing, and 
three-point bending) of bone strength.  
 Because of their two distinct mechanisms of action, namely the anabolic 
response that has been demonstrated via mechanical loading and the anti-catabolic 
characteristics of ZA, we investigated the interaction of these two treatments for the 
protection of disuse bone loss.  We hypothesized that cotreatment would fully rescue 
HU-induced deteriorations in bone mass, microarchitecture, and strength.  A similar 
concept has been explored clinically, where the anabolic therapy parathyroid hormone 
(PTH) was used in combination with various anti-resorptive bisphosphonates in 
postmenopausal women (140-143) and in aging men (144,145).  Cosman et al. 
administered a single intravenous infusion of ZA (5 mg) with daily subcutaneous 
injections of teriparatide (recombinant human PTH (1-34), 20 µg) in postmenopausal 
women with osteoporosis and showed that the combination was superior to monotherapy 
at improving BMD in the hip and the spine (142).  These results suggest that increases in 
bone mass were not disrupted by concomitant use of ZA.  Alternatively, studies using 
alendronate in both men (144) and postmenopausal women (141) have revealed a 
blunting effect of alendronate when taken with PTH.  That is, PTH treatment alone was 
more successful at augmenting hip and spine BMD than combined therapy.  
Inconsistences between these studies may be attributed to the type of bisphosphonate 
used or the timing in which treatments were administered.  Since bisphosphonates 
reduce bone resorption by specifically targeting osteoclasts, bone turnover, because of 
coupling, reduces as well.  Thus, when administered simultaneously, bisphosphonates 
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have the potential to reduce the anabolism of PTH.  This concept was investigated in the 
PaTH (PTH + alendronate) study (140).  Combining alendronate with PTH yielded no 
clear advantage over PTH alone, yet when taken sequentially, rather than concurrently, 
the effect was more beneficial than monotherapy, suggesting that anabolic treatment 
should be followed by an anti-resorptive.  These findings are in accordance with ours, as 
the sequential combination of Ex and ZA rescued losses in mass, density, and 
microarchitecture beyond singular Ex or ZA. 
 In a follow-up study to PaTH, Keaveny and colleagues compared the effects of 
PTH and alendronate combinations on the femoral neck mechanical strength of 162 
postmenopausal osteoporotic women (146).  To determine strength, QCT images were 
converted to finite element models and virtually tested in a sideways fall configuration.  
Because bone strength and, ultimately, fracture risk are biomechanical phenomena, it is 
important to relate underlying treatment-induced changes in mass, density, and 
architecture to fracture risk.  In this study, similar to previous densitometric PaTH 
findings, improvements in strength were more beneficial when alendronate followed 
PTH than in any other combination explored.  These strength changes, however, were 
poorly correlated to BMD (r2 = 0.14), demonstrating the importance of assessing bone 
quality beyond densitometry alone.  Although this study is unique in that it is the first to 
clinically assess different treatment combinations using FEA, orthopaedic biomechanics 
research has utilized the finite element technique for decades (147).  More recently, 
cadaver studies consistently demonstrated that FEA accurately predicts bone strength 
superior to DXA or QCT measurements of BMD (148-150).  Another benefit of FEA is 
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its ability to discriminate between the individual roles of the cancellous and cortical 
compartments under loading.  Twenty-eight days of HU significantly increased the ratio 
of cortical-cancellous loading in the present study, ultimately subjecting the cortex to 
higher stresses and a consequent greater probability of fracture at that site. Treatment 
with Ex or ZA alone returned load sharing values back to control levels while cotherapy 
surpassed them.  Mechanical stiffness followed similar trends as load sharing, where 
sequential treatment was the most salubrious option tested.  It is worth noting that 
differences in stiffness were largely underrepresented by changes in vBMD.  That is, HU 
reductions in vBMD were half the magnitude of stiffness reductions.  Similar findings in 
sclerostin antibody-treated mice were demonstrated with a comparable FEA load sharing 
technique (67).  While FEA currently provides the best clinical estimation of mechanical 
strength, it remains limited by the fact that it does not directly incorporate tissue 
properties beyond radiological density.  Thus, direct measurement of bone strength may 
be an important supplement to CT-derived FEA techniques.    
 Reference point indentation (RPI) is a direct measurement of bone material 
properties capable of being employed both in vivo and ex vivo.  In our study, we 
investigated the ex vivo mechanical strength of the diaphysis femur.  Neither HU nor 
treatment resulted in any significant changes in microindentation measurements.  That is, 
we were not able to discriminate between loading status, simulated exercise, ZA, or the 
combination with RPI.  These findings are consistent with cortical µCT results along the 
femur diaphysis.  Since RPI inherently evaluates cortical bone only, it was not entirely 
surprising, based on the minimal changes in cortical densitometry at that site, that we did 
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not finding significant changes in any microindentation measurements.  It is well known 
that cortical bone is less metabolically active than its cancellous counterpart.  Thus, it is 
possible that neither HU nor treatment influenced femoral diaphysis cortical bone, even 
though both significantly affected metaphyseal cancellous bone.  An alternative 
explanation could be that RPI was simply not sensitive enough to capture subtle changes 
among our groups.  Since this is the first study to our knowledge to use ex vivo RPI in 
previously unloaded rats, we do not know if our findings are an aberration or if 
microindentation is indeed not capable of discriminating against subtle changes in 
unloaded rat femurs.  RPI can, however, detect age-related changes in porcine femoral 
cortical bone (151).  Indentation distance increase (IDI), total indentation distance (TID), 
and average unloading slope (US) all significantly decreased with age in 1- to 48-month 
old pigs.  Because RPI is a relatively new technique, however, it remains to be 
determined how these variables relate to material properties as measured by traditional 
biomechanical testing.  Compared to standard three-point bending data, US was found to 
be positively correlated to material stiffness and IDI to be negatively correlated to 
material toughness (90).  Taking these findings to be accurate, IDI results from the 
former study conducted in pigs would indicate a decrease in material stiffness and an 
increase in material toughness with age (151).  Whereas we did not find differences in 
IDI in ZA and non-ZA treated rats, Gallant et al. showed higher IDIs in alendronate 
versus vehicle treated dogs (90).  These findings are consistent with the growing concern 
that long-term bisphosphonate use may deteriorate bone material properties, including 
toughness, which could lead to atypical femoral fractures (AFF).    
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  Unlike “typical” femoral fractures, which are common in the femoral neck and 
intertrochanteric hip, AFFs occur with a short oblique orientation in the subtrochanteric 
and shaft regions of the femur with the radiographic appearance of a stress or fatigue 
fracture (152).  Although registry studies have not found causation between 
subtrochanteric and femoral shaft fractures and bisphosphonate usage (153-155), and 
despite the occurrence of AFFs in bisphosphonate-naïve patients, collective evidence 
does suggest an association between long-term bisphosphonate use and AFFs. While the 
etiology of these atypical fractures remains unknown, a number of potential mechanisms 
have been suggested.  To begin, because bisphosphonates reduce bone resorption, they 
inherently reduce bone turnover as a consequence, which in turn may lead to increased 
accumulation of skeletal microdamage.  Although we did not show a decrease in bone 
toughness at the femoral neck in the present study, bisphosphonate-associated increases 
in microcracks can lead to decreased structural performance of bone (e.g., dog ribs), 
including mechanical toughness (156).  Thus, insufficiency subtrochanteric and femoral 
shaft fractures may be explained by reductions in bone turnover inherent of long-term 
bisphosphonate treatment.  It is worth noting, however, that bone remodeling doubles 
within 12 months of menopause, triples by age 60, and remains elevated if left untreated 
(157).  Treatment with bisphosphonates reduces remodeling back to values within the 
range of healthy women prior to menopause (158).  Although the occurrence of AFFs is 
rare, comprising less than 1% of all hip and femur fractures (152), some patients, such as 
those treated with glucocorticoids (GCs), are at an increased risk of both atypical and 
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typical femoral fractures (159).  In fact, GC treated patients may benefit from a 
sequential, prophylactic treatment protocol rather than a reactive one.  
The American College of Rheumatology estimates that 20% of all osteoporosis 
cases are due to the chronic (>6 months) use of GC medications (160).  In fact, GC-
induced osteoporosis is the most common form of drug-induced osteoporosis (161).  
Within the first five to seven months of GC therapy, bone volume declines by as much 
as 27% (162).  This rapid loss of bone is over 20 times the rate of losses experienced by 
postmenopausal women, leaving patients at a heightened risk of spontaneous, and often 
asymptomatic, bone fracture.  Bone fractures occur in as many as 30–50% of patients 
treated with GCs (163,164).  Because of the high mortality rate of hip fractures in 
individuals over the age of 50 (24% within the first year of the fracture), it is critical for 
bone health to be closely monitored and evaluated for treatment before, during, and after 
GC therapy (165).  However, less than one-half of patients receiving GC therapy are 
evaluated for osteoporosis and less than 14% actually receive treatment (166,167).  
Various treatment interventions have been explored in an effort to mitigate GC-induced 
osteoporosis.  Still, over 97% of patients receiving GC therapy may experience 
significant bone loss and increased fracture risk (168).   
Bisphosphonates are the current gold standard treatment option for GC-induced 
bone loss.  Relative successes using bisphosphonate therapy as treatment for GC-
induced bone loss have been shown.  Use of bisphosphonates reduce the risk of GC-
induced bone fracture in post-menopausal women (169). Furthermore, Braith et al. 
revealed that the combination of resistance exercise and bisphosphonate treatment 
 82 
 
mitigated BMD losses in GC-treated lung transplant patients (170).  However, treatment 
interventions (bisphosphonate and bisphosphonate plus resistance exercise) were not 
started until 3 and12 months after the initiation of GC therapy, respectively. Thomas et 
al. (169) note that after 3 months of GC therapy, before the initiation of bisphosphonate 
treatment, patients had already experienced significant bone loss.  Patients in the latter 
study were already at an increased fracture risk as high as 50% at the initiation of bone 
loss treatment (163,164,170).   Currently, there are no clinical pre-treatment 
prescriptions for GC-induced osteoporosis. Thus, it is imperative to treat GC patients 
proactively rather than reactively to prevent the consequentially rapid and deleterious 
bone loss from GC therapy.  Although the impetus for bone loss is quite different 
between GCs and HU, the current study has important clinical implications that could 
shift the current practice of treating patients for GC-induced bone loss post therapy to a 
novel prophylactic modality.  
 We have demonstrated here that monotherapy with ZA or high impact Ex 
mitigated HU-induced declines in mechanical properties at the femoral neck and femoral 
metaphysis, while sequential cotreatment completely prevented them.  Consistent with 
CT-derived declines in mass, density, and microarchitecture evaluated at the femur, 28 
days of unloading caused marked declines in bone quality, such as stiffness and 
toughness, whereas pre-treatment with Ex and/or ZA rescued these losses.  Our results 
are consistent with PaTH data suggesting that anabolic treatment should precede an anti-
resorptive in order to maximize treatment efficacy.  That is, we have shown that the 
timing of anabolic and anti-catabolic therapies is important for the prevention of bone 
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loss.  This study has profound clinical implications as patients exposed to GCs may 
benefit from a prophylactic, rather than post-operative, therapy regimen to counter GC-
induced fracture risk. 
Bone Turnover: Systemic Resorption and Cortical Formation 
 The primary bone turnover findings in this study are threefold.  First, cortical 
bone formation was drastically reduced with HU while markers of bone resorption were 
significantly enhanced.  Second, ZA treatment did not further reduce formation but it did 
reduce resorption.  Finally, we did not detect any effect of Ex on bone formation or 
resorption. 
 Both the structural and material properties of bone are affected by the rate at 
which bone is turned over.  That is, bone remodeling plays an integral role in both the 
extrinsic and intrinsic characteristics of bone health.  Spinal cord injury, long-term bed 
rest, and spaceflight each negatively alter bone turnover.  In December 2001, the launch 
of 24 ten-week old mice on STS-108 marked an opportunity to investigate spaceflight-
induced changes in bone turnover in rodents (171).  Bone formation in flight mice, 
assessed by quantitative histomorphometry, was reduced up to 60% versus controls.  
Similar to what has been observed in rodents flown on shuttle missions, bone turnover is 
significantly altered in rodents exposed to HU (82).  Twenty-one days of HU in 12-
week-old female mice suppressed cancellous MAR (distal femur) by over 50% (67).  In 
adult male rats, 28-day HU produced similar reductions in MS/BS, MAR, and BFR rate 
in proximal tibia cancellous bone (82).  Similar decrements in bone formation on long 
bone diaphyseal surfaces have been shown in cortical bone on both periosteal and 
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endocortical surfaces (83).  The present study demonstrated similarly drastic reductions 
in bone formation as a result of 28 days of HU.  These BFR reductions, however, did not 
correspond to subsequent loss of mass, density, shape, or strength at that site.  It is likely 
that if the HU were taken out for a longer period of time, reduced BFR would in turn 
reduce bone quality as well.   
 Surprisingly, increased mechanical loading in our Ex animals did not increase 
MS/BS, MAR, or BFR in mid-shaft tibia, nor did it mitigate HU-induced declines in 
these variables.  We conjecture that the strain environment experienced in the diaphysis 
tibia of Ex animals surpassed the osteogenic threshold.  That is, based on the theory of 
Harold Frost (172), it is possible that our loading paradigm over-strained the tibia 
beyond what would be experienced in physiological conditions, rendering it 
unsuccessful at enhancing bone formation at that site.  Future studies may seek to 
investigate this hypothesis by using strain gauge measurements in drop-trained animals 
to quantify the precise strains experienced during landing.  Our histomorphometric 
findings are consistent, however, with pQCT and strength measurements in the mid-shaft 
tibia where BFR was evaluated.  BFR was measured in one other study which utilized a 
similar free-fall, high-impact drop training as in the present study (119).  Lin et al. 
determined that short-term exposure to drop training increased ulna BFR approximately 
80%, but hindlimb histomorphometry was not reported.  Thus, our results should be 
considered with caution, as this is the first study to our knowledge to investigate 
hindlimb BFR in drop trained rodents.  While Ex did not inhibit HU-induced losses in 
bone formation, ZA did not further reduce them.  These findings are at odds with others, 
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as ZA administered to suspended mice further reduced bone formation (111).  
Differences between our study and Lloyd et al. may explain the conflicting results.  To 
begin, the HU period in our study was twice the length of theirs.  Thus, our longer HU 
regimen may have overpowered our ability to detect subtle ZA-induced BFR changes.  
Secondly, they used growing mice whereas we studied skeletally mature rats. It is 
possible that growing mice react differently to ZA and HU coupled treatment than adult 
rats.       
 Conflicting results exist for whether bone resorption increases in rodents in 
response to HU.  Some studies report a doubling of the bone resorption marker TRAcP 
5b following HU in skeletally mature mice (173), while others using young rats mark no 
change (75).  A potential explanation for these discrepancies may be differences in 
animal weight changes during unloading.  When animals do not gain weight, osteoclast 
number from HU is no different than controls (174,175).  Conversely, when HU causes a 
gain in animal body weight, osteoclast activity is increased (176,177).  Although HU 
caused a slight decrease in body weight in the present study, serum TRAcP 5b levels 
were elevated.  HU studies consistently report dramatically suppressed bone formation 
without any corresponding drop in bone resorption.  This uncoupling of formation and 
resorption in response to reduced mechanical loading inevitably leads to a net loss in 
bone mass and likely declines in bone quality.  To combat this uncoupling, ZA treatment 
significantly reduced bone resorption in ZA+HU and Ex+ZA+HU animals.  Uncoupled 
bone remodeling is of great interest to NASA, as long duration spaceflight has been 
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shown to increase bone degradation without subsequent increases in bone formation 
(25).        
Addressing Key Concerns of the NASA Bone Summit  
 Spaceflight-induced bone loss is not a new phenomenon to the space program.  
In the early 1970s, data from Skylab revealed musculoskeletal losses and increased bone 
resorption during long-duration missions (178).  Even with robust exercise equipment 
available on Mir, X-ray absorptiometry (DXA) measurements document rapid declines 
in BMD in the lower limbs, hip, and spine, as well as elevated resorption with 
nonsignifiant changes in formation (179).  These findings extended to the International 
Space Station (ISS), where added exercise equipment, called the interim Resistive 
Exercise Device (iRED), was unable to prevent average monthly BMD losses of 2.3% in 
the total hip and even greater declines in estimated strength (180).  To combat these 
losses, a similar, yet more sophisticated, machine called the Advanced Resistive 
Exercise Device (ARED) was placed on the ISS in 2008 (181).  Unlike iRED, which was 
only capable of producing up to 300 pounds of resistive force, ARED produced twice 
that with the added benefit of user-friendly interfacing.  With this new technology, 
spaceflight-induced bone degradation was significantly reduced (25).  Concern 
remained, however, with heightened levels of in-flight markers of resorption.  As an 
adjunctive countermeasure, NASA considered the use of an anti-resorptive 
bisphosphonate (alendronate) to be taken in conjunction with the 2.5 hours of currently 
prescribed daily exercise.   
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Very recent data from LeBlanc et al. show promising protection from almost all 
measures of bone mass, architecture, and strength losses, along with sustained in-flight 
levels of bone resorption (182).  While encouraging, a major drawback of oral 
bisphosphonates, such as alendronate, is the adverse upper gastrointestinal (GI) effects 
that may be exaserbated in microgravity.  Twenty percent (n=2 out of 10 astronauts) of 
the participants in this study were forced to withdraw from treatment because of GI 
issues.  This contraindication was recognized by the NASA Bone Summit, a panel of 
experts at the Johnson Space Center (JSC), which convened in 2010 to discuss the 
adverse events of prolonged periods of microgravity and to make recommendations for 
in-flight treatment and post-flight surveillance based on  the current long-duration 
astronaut database (183).  For several listed reasons, the Summit recommended the use 
of an intravenous (IV) infusion of ZA administered prior to flight.  To begin, ZA use is 
not associated with the adverse GI issues of their oral counterparts.  Second, a pre-flight 
IV infusion of ZA would eliminate the need for weekly oral doses of alendronate while 
in flight.  Finally, since ZA would be administered prior to flight, flight surgeons would 
be permitted to assess any drug side effects while crew members were still on Earth.   
Due to these recommendations, the current study was designed in large part to 
answer key questions raised by the NASA Bone Summit.  Carefully designed animal 
studies must be completed before NASA will make definitive recommendations for 
future missions aimed beyond low-Earth orbit.  For the first time in the rat model, ZA 
was shown here to completely rescue disuse-induced alterations in bone mass, geometry, 
microarchitecture, and strength.  Furthermore, it prevented increases in a marker of bone 
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degradation.  Consistent with our hypothesis, sequential high-impact loading and ZA 
countermeasures completely protected against microarchitectural and strength losses.  
As NASA aims to embark on missions potentially lasting for up to 30 months (i.e., 
habitation of Mars), our study provides valuable data that could have large implications 
for important future treatment options for crew members.     
This study is not without limitations.  We did not subject fully weight bearing 
animals to Ex, ZA, or the combination.  That is, only unloaded animals were provided 
treatment.  Clinically, it would be beneficial to know whether the additional benefits of 
our sequential therapy translate to patients not removed from gravitational loading. 
Furthermore, as mentioned prior, strain on bone induced by our loading protocol was not 
quantified in this study, making predictions about site-specific strain environments 
during high-impact landing purely speculatory.  Although limited, findings from this 
study demonstrate that a single injection of ZA was capable of rescuing disuse-induced a 
in bone mass, density, and strength, while preventing systemic increases in bone 
resorption without further suppressing cortical bone formation.  When coupled with 
mechanical loading, Ex+ZA not only protected against the aforementioned losses, in 
some instances it facilitated gains in a site-specific manner.  
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CHAPTER V  
 
CONCLUSION 
 
 
In the present study, we found that monotherapy using either high-impact, free-
fall simulated exercise or a single injection of ZA rescued adverse densitometric and 
microarchitectural changes associated with 28 days of HU.  When administered together, 
our sequential regimen completely protected against these disuse-induced alterations in a 
site-specific manner.  In the DFM, for example, combination treatment was superior to 
either alone.  Measurements of bone strength were also assessed.  Whereas neither 
loading status nor drug treatment altered material properties evaluated by RPI and three-
point bending, µFE analysis was successful at discriminating against these differences.  
In terms of bone quality, densitometry appears to underestimate the reaction of bone 
measurements to unloading, overloading, and drug therapy.  While we cannot definitely 
state which is superior, strength measurements via µFE analysis may be able to capture 
disuse effects on bone beyond current CT capabilities.  Analysis of bone turnover 
through dynamic histomorphometry and serum TRAcP 5b was investigated to elucidate 
the effect of HU and treatment combinations on remodeling.  HU amplified bone 
degradation without an associated increase in bone formation, suggesting an uncoupling 
of these two activities during disuse.  ZA treatment effectively prevented inclines in 
bone resorption without affecting bone formation.  Although Ex did not increase bone 
formation, when combined with ZA, it did provide greater protection at some sites than 
either treatment alone, suggesting some benefit beyond what was captured by BFR 
measurements. 
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Results from this study have both clinical and spaceflight applicability.  GC-
treated patients, for example, are left at an extremely high risk of bone fracture 
immediately following treatment.  Although the modality of bone loss is quite different 
between disuse and GCs, our data could shift the current standards of treating GC-
patients post-operation to a prophylactic regimen that would aim to prevent, rather than 
simply treat, GC-induce bone loss.  In line with the NASA Bone Summit 
recommendations for future treatment options for long-duration astronauts, and in 
response to their call for carefully designed animals experiments to test these options, 
our study may be used to help guide flight surgeons on the potential use of ZA and 
exercise to counter spaceflight-induced increased fracture risk and premature 
osteoporosis.                    
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Abstract 
Astronauts on long duration missions continue to experience bone loss, as much 
as 1 – 2% each month, for up to 4.5 years after a mission.  Mechanical loading of bone 
with exercise has been shown to increase bone formation, mass, and geometry.  The aim 
of this study was to compare the efficacy of two exercise protocols during a period of 
reduced gravitational loading (1/6th body weight) in mice. Since muscle contractions via 
resistance exercise impart the largest physiological loads on the skeleton, we 
hypothesized that resistance training (via vertical tower climbing) would better protect 
against the deleterious musculoskeletal effects of reduced gravitational weight bearing 
when compared to endurance exercise (treadmill running).  Young adult female 
BALB/cBYJ mice were randomly assigned to three groups: 1/6g (G/6; n=6), 1/6g with 
treadmill running (G/6+RUN; n=8), or 1/6g with vertical tower climbing (G/6+CLB; 
n=9).  Exercise was performed five times per week.  Reduced weight bearing for 21 days 
was achieved through a novel harness suspension system.  Treadmill velocity (12 – 20 
m/min) and daily run time duration (32 – 51 min) increased incrementally throughout the 
study. Bone geometry and volumetric bone mineral density (vBMD) at proximal 
metaphysis and mid-diaphysis tibia were assessed by in vivo peripheral quantitative 
computed tomography (pQCT) on days 0 and 21 and standard dynamic 
histomorphometry was performed on undemineralized sections of the mid-diaphysis 
after tissue harvest.  G/6 caused a significant decrease (P<0.001) in proximal tibia 
metaphysis total vBMD (-9.6%).  These reductions of tibia metaphyseal vBMD in G/6 
mice were mitigated in both G/6+RUN and G/6+CLB groups (P<0.05). After 21 days of 
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G/6, we saw an absolute increase in tibia mid-diaphysis vBMD and in distal metaphysis 
femur vBMD in both G/6+RUN and G/6+CLB mice (P<0.05). Substantial increases in 
endocortical and periosteal mineralizing surface (%MS/BS) at mid-diaphysis tibia in 
G/6+CLB demonstrate that bone formation can be increased even in the presence of 
reduced weight bearing.  These data suggest that moderately vigorous endurance 
exercise and resistance training, through treadmill running or climb training mitigates 
decrements in vBMD during 21 days of reduced weight bearing.  Consistent with our 
hypothesis, tower climb training, most pronounced in the tibia mid-diaphysis, provides a 
more potent osteogenic response compared to treadmill running. 
 
Keywords 
partial weight bearing; exercise; spaceflight; histomorphometry  
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1. Introduction 
   Spinal cord injury, muscle paralysis, and prolonged bed rest have all been 
shown to elicit increased bone resorption, decreased bone mass, and a consequent 
increased risk of bone fracture (1, 2, 18).  The observed bone loss under these conditions 
is commonly attributed to reduced mechanical loading to bone tissue (23). During low-
Earth orbit, astronauts aboard the International Space Station (ISS) can lose up to 2% 
bone mineral density (BMD) at the hip per month while in micro-gravity (13).  This 
level of bone loss in astronauts is an order of magnitude greater than the rate of loss in 
post-menopausal women, a population at high risk of developing osteoporosis on Earth 
(7).  Decreased BMD and altered bone geometry are strongly associated with increased 
risk of fracture (3). Finite element modeling analyses reveal that femoral neck strength 
decreases an average of 2.5% each month during long duration ISS missions (12).  Upon 
returning to Earth, femoral neck volume and trabecular BMD (tBMD) remain below pre-
flight values for up to 4.5 years, compromising the long-term skeletal health of crew 
members, especially those selected for repeat ISS missions (4). 
 The tail suspended hindlimb unloaded (HU) rodent has become a well-
established ground-based analogue for investigating the skeletal adaptations of 
spaceflight (17).  The HU model simulates spaceflight conditions by reducing 
mechanical loads to the hindlimbs and inducing a cephalic shift of fluids, both 
deleterious to bone (14, 22)  With the National Aeronautics and Space Administration’s 
(NASA) growing interest in returning to the Moon, a near-Earth asteroid, or Mars, it is 
becoming increasingly important to determine if  added resistance exercise protects the 
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musculoskeletal unit during space missions.  Results from our lab using a novel partial 
weight bearing suspension apparatus have demonstrated that partial weight bearing, and 
in particular 3/8th body weight (Martian gravity) and 1/6th body weight (Lunar gravity), 
does not protect against bone loss observed with the full unloading of traditional tail 
suspension (26).  As a result, countermeasures must be considered to protect against 
bone loss in partial gravity environments, but we are not aware of any data testing 
exercise countermeasures for bone loss in a reduced weight bearing environment such as 
the Moon.   
The aim of this study was to investigate two different exercise programs during a 
period of reduced mechanical loading as potential countermeasures to bone loss.  
Exercise, both aerobic and resistive, can be osteogenic and may effectively mitigate or 
prevent bone loss during partial weight bearing (19).  We hypothesized that both aerobic 
exercise (G/6+RUN) and resistance exercise (G/6+CLB) during 21 days of 1/6th gravity 
(G/6) would mitigate bone loss in the femur and tibia of adult mice.  We further 
hypothesized that resistance exercise would be more protective than a running regime.       
 
2. Materials and Methods 
2.1. Animals and Experimental Design 
 Twenty-three 10-week old female BALB/cByJ mice were obtained from Jackson 
Laboratories (Bar Harbor, Maine) and allowed one week of acclimation before the 
initiation of the study.  Throughout the study, animals were singly housed in a 
temperature controlled room (23 ± 2°C) with a 12:12-h light-dark cycle, provided water 
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ad libitum, and fed a standard rodent chow diet (Harlan Teklad 8604). Animal care and 
experimental procedures from this study were approved by Texas A&M University’s 
Institutional Animal Use and Care Committee (IACUC).  The health of all animals was 
monitored daily through frequent standard health checks and body weight logs.   
 Following acclimation, animals were block assigned to one of three groups by 
body weight: 1) 1/6th weight bearing group to simulate Lunar gravity (G/6, n=6), 2) 1/6th 
weight bearing group with climbing resistance exercise (G/6+CLB, n=9), and 3) 1/6th 
weight bearing group with treadmill running (G/6+RUN, n=8).  Intraperitoneal 
injections of calcein (Sigma Chemical, St. Louis, 15 mg/kg body weight) were 
administered seven and two days prior to the end of the study to quantify the rate of new 
bone formation.  On day 21, all animals were anesthetized with a cocktail of ketamine 
(75 mg/kg body weight) and medetomidine (1.0 mg/kg body weight) then euthanized by 
cardiac puncture exsanguination and cervical dislocation.  Femora and tibiae were 
excised from animals, stripped of soft tissue, and stored in either PBS-soaked gauze at -
30°C for mechanical testing or in 70% ethanol at 4°C for histomorphometry analyses.   
 
2.2. Partial Weight Bearing Suspension 
 A partial weight bearing suspension system was utilized to simulate Lunar (1/6th) 
gravitational loading in mice (26, 27).  Briefly, mice were single-housed in 13 in3 
custom built cages made of clear polycarbonate walls with removable polypropylene 
perforated floors.  A stainless steel aluminum rod, settled across the top of the cage, 
contained a small nylon wheel and low friction bearing that decreased resistance to 
 114 
 
movement of the suspended animals.  Mice were suspended horizontally in order to 
reduce weight bearing of the forelimbs and hindlimbs equally.  Forelimbs were 
supported by a shoulder jacket made of moleskin, athletic tape, and Velcro.  Jackets 
were designed to allow for normal activities (e.g., eating, drinking, and grooming).  
Support for the hindlimbs was achieved by first applying SteriStrip (3M, St. Paul, MN) 
loosely around the base of the tail to reduce irritation then wrapping athletic tape around 
the SteriStrip.  To minimize stress to the animals, jackets and tail wraps were applied 
and conducted under isoflurane anesthesia.  All mice were weighed and 1/6 weight 
bearing titrated daily.  Full body weight was measured by suspending the whole mouse 
in a custom made titration frame, built to precisely the same floor-to-rod height as the 
suspension cages, placed on an electronic scale (Ohaus Corp., Pine Brook, NJ)  To 
adjust for daily changes in body weight, mice were placed in the titration column and, by 
adjusting the linear tension spring (spring constant of 0.7 N/m ) and eye bolt, were 
titrated to the desired 1/6th weight-bearing (± 0.1 g).           
 
2.3. Exercise 
Prior to each exercise bout in G/6+RUN and G/6+CLB groups, animals were 
removed from harness and allowed to exercise at full weight bearing.  Upon completion 
of daily training protocols, which lasted for approximately 45-60 minutes, animals were 
re-harnessed under brief isoflurane anesthesia to minimize stress and returned to partial 
weight bearing in the suspension cages.          
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Animals in G/6+RUN performed moderately intensive aerobic exercise five 
times/week for three weeks on a six-lane motorized rodent treadmill with rear shock grid 
(Columbus Instruments, Columbus, OH) as described previously (15).  Animals were 
familiarized with treadmill running on the first two days of training to eliminate training 
adaptations.  Following the acclimation period, treadmill speed and intensity increased 
throughout the study, peaking at 20 meters/minute for 45 minutes at a 10° incline.  All 
animals were successful at completing the three week training protocol in its entirety.  
 Voluntary resistance exercise was performed by all G/6+CLB animals by 
climbing a 1-meter, vertical, wire-meshed tower five times/week for three weeks.  The 
tubular climb tower, designed and built in our laboratory, was made of steel mesh with 
cross-stripes spaced 5 mm apart.  The tower diameter was 5 cm to allow animals to 
easily fit and climb inside.  A 5 cm hole was bored out of the bottom of a standard 
mouse cage where the tower could be attached and supported.  Climb repetitions began 
by placing the animal at the base of the tower where they were allowed to climb up the 
length of the tower and motivated, when needed, by a small fishing bobber looped 
through the tower.  Climbs were considered complete when animals reached the base of 
the attached cage (top of the climb tower) where they could be retrieved by the trainer.  
Consistent with the treadmill protocol, tower climbing was designed to be a progressive 
training program to accommodate for daily improvements.  Small lead split-shot pellets 
were wrapped in athletic tape to achieve incremental increases in total weight (up to 
175% animal body weight) and loosely bound to the animals at the tail base.  Daily 
climb number decreased (from 50 down to 36 climbs) as attached tail weight increased 
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(from 0 up to 100% body weight), peaking at 36 climbs with 175% body weight so that 
total work performed remained constant.  Number and duration of completed climbs 
were observed and recorded.  A typical training session lasted for approximately one 
hour.   
 
2.4. Peripheral Quantitative Computed Tomography (pQCT) 
2.4.1. In vivo pQCT Densitometric Test 
 Under isoflurane anesthesia, left tibiae were scanned in vivo at baseline (day 0) 
and at the end of the study (day 21) using an XCT Research-M device (Stratec Corp., 
Norland, Fort Atkinson, WI).  A hydroxyapatite cone phantom was used to calibrate the 
machine daily.  Scan sites included two slices at the mid-diaphysis (50% bone length) 
and three slices at the proximal metaphysis.  Tibiae were scanned with a speed of 2.5 
mm/sec, a voxel resolution of 100 μm2, and a scan thickness of 500 μm.  For analysis, 
proximal metaphysis outer and inner thresholds were set at 400 mg/cm3 and 750 
mg/cm3, respectively.  Diaphyseal threshold was set at 750 mg/cm3.  Machine precision, 
based on manufacturer data, is ±9 mg/cm3 (cortical vBMD) and ±3 mg/cm3 (trabecular 
vBMD).  Measurement parameters, such as total vBMD, were obtained by averaging the 
three slices at the proximal metaphysis and the two slices at the diaphysis.     
 
2.4.2. Ex vivo pQCT Densitometric Test 
 After termination, excised right femurs stripped of soft tissue were scanned ex 
vivo with a speed of 2.5 mm/sec, a voxel resolution of 70 μm2, and a scan thickness of 
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500 μm.  Three slices at the proximal metaphysis and two slices at the mid-diaphysis 
were scanned and the means of these slices were used for analysis.  At the diaphysis, 
cross-sectional moment of inertia (CSMI) was used in combination with three-point 
bending data (Table 3) as estimates of strength as described previously (22).         
 
2.5. Three-Point Bending Biomechanical Test 
 Once thawed to room temperature, right femora were tested to failure in three-
point bending on an Instron 3345 machine (Norwood, MA; 100 N load cell; Bluehill v. 
2.14.582) as described previously (10).  Using precision hand calipers, the anterior-
posterior and medial-lateral periosteal diameters at the mid-diaphysis were measured and 
recorded.  Each bone was then placed anterior side down on metal pin supports (D= 3.0 
mm) spaced 10 mm apart.  To perform the test, a quasi-static load of 2.54 mm/minute 
was applied to the upper part of the diaphysis region corresponding with pQCT 
diaphysis scan site (50% total bone length).  The test proceeded until fracture occurred.  
Load and displacement data were collected during tests (at 10 Hz) and analyzed using 
Bluehill software (version 2.14.582, Instron Bluehill) and a custom-written Matlab 
(version 7.12.0, TheMathWorks, Inc.) program.  Later, load-displacement data were 
analyzed using Matlab (The Mathworks, Inc.; Natick, MA).  Stiffness (k, N/mm) was 
determined by calculating the slope of the load-displacement curve in the elastic region.  
Ultimate load (N) designated the largest force achieved throughout the test.  Energy 
absorbed (N·mm) was determined as the area under the entire load-displacement curve.  
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From classical beam bending theory, elastic modulus (E, GPa) was obtained using the 
equation E = (k·S3) / (48·CSMI·1000), where S = support span distance (10 mm). 
 
2.6. Histomorphometry 
 Intraperitoneal injections of calcein (15 mg/kg body weight, Sigma Chemical, St. 
Louis, MO) were administered at seven and two days prior to termination to label 
mineralizing surfaces.  Undemineralized excised distal right tibia were dehydrated and 
embedded in methyl-methacrylate (Sigma-Aldrich M5, 590-9, St. Louis, MO).  Serial 
cross sections (150-200 μm thick) were cut using a diamond wafer low-speed saw 
(Buehler, Lake Bluff, IL) starting1 mm proximal to the tibia-fibular junction.  
OsteoMeasure Analysis Software, version 1.3 (OsteoMetrics, Atlanta, GA) was used to 
analyze each specimen and determine mineralizing surface/bone surface (MS/BS), 
mineral apposition rate (MAR), and bone formation rate (BFR = MS/BS · MAR).  
Histomorphometric analyses follow the standardizations as defined previously (5).  
 
2.7. Statistical Analysis 
 All data are presented as mean ± standard error of the mean (SE) and were 
evaluated for differences using SigmaStat, version 3.5 (Systat Software Inc., San Jose, 
CA).  A two factor ANOVA (exercise and time) with repeated measures on time was 
used to evaluate differences among in vivo pQCT data.  Post hoc pairwise comparisons 
were made using the Tukey Test.  All other statistical analyses were made using a one 
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factor ANOVA with the Holm-Sidak method for pairwise comparisons.  Statistical 
significance was determined with p<0.05.   
 
3. Results 
 Body weight in all groups was maintained throughout the 21 days of the study.  
Slight initial declines in weight (≤ 2 grams) occurred, but were not significant (Figure 1).  
Overall, mice appeared healthy and exhibited normal drinking and feeding   
Partial weight bearing for 21 days caused a decrease in total vBMD at the tibia 
metaphysis.  These losses were attenuated in both exercise groups (Figure 2).  At day 21, 
in vivo tibia and ex vivo femur metaphysis vBMD were higher in G/6+RUN and 
G/6+CLB compared to G/6 (Table 1).  Marrow area in tibia metaphysis is elevated with 
partial weight bearing compared to G/6+RUN (P=0.051).  Exercise modalities increased 
tibia diaphysis cortical vBMD by 3.2% in G/6+CLB and by 2.9% in G/6+RUN (Figure 
3).     
Ex vivo scans at day 21 revealed that femur metaphysis total BMC and total 
vBMD were significantly higher in exercising G/6 mice than in G/6 animals (Table 2), 
suggesting a mitigation of bone loss during G/6 at this site.  However, at the femoral 
diaphysis these ex vivo measures demonstrate no effect of G/6 or exercise after 21-days.  
Tibia diaphysis bone formation was heightened with resistance exercise during 
partial weight bearing compared to G/6 alone (Figure 4).  Percent mineralizing surface 
(MS/BS) was over 6-fold higher in G/6+CLB mice at the periosteal surface and over 9-
fold higher at the endocortical surface versus that observed in G/6.  Due to an absence of 
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double labels in all animals, mineral apposition rate (MAR), and thus bone formation 
rate (BFR), could not be determined.   
Three-point bending biomechanical testing of the tibia diaphysis yielded no 
significant differences among groups (Table 3).  Neither resistance nor aerobic exercise 
increased bending strength during a period of 21-day partial weight bearing.         
 
4. Discussion  
 The purpose of this study was to compare two different modalities of exercise 
during a period of partial weight bearing and to determine their ability to mitigate disuse 
bone loss.  In accordance with Frost’s mechanostat theory, we hypothesized that the 
higher magnitude loading imposed by resistance exercise (climbing protocol) would 
have a more robust beneficial effect compared to aerobic exercise (treadmill running) 
(9). Consistent with results from previous studies using partial weight bearing (6, 25) 
and the  full unloading of traditional tail suspension (11) in adult mice, significant bone 
loss occurred after 3 weeks of 1/6 partial weight bearing (G/6) in the tibia metaphysis, a 
site sensitive to disuse bone loss.   The effect of exercise in mitigating losses, however, 
appeared to be site-specific.  At the metaphysis, neither treadmill running nor tower 
climbing was able to protect against total vBMD losses. However, vBMD values at the 
end of the study were higher compared to partial weight bearing in the absence of 
exercise, suggesting an exercise-induced mitigation of losses.  Contrary to the 
metaphysis, the tibia diaphysis appears to show possible beneficial effects of exercise, 
but the results are equivocal.  Exercise was able to elicit an anabolic response despite 
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simultaneous exposure to G/6.  Even though cortical vBMD increased over 21 days in 
both G/6+RUN and G/6+CLB, it also increased slightly for G/6 alone.  Further, 
comparing groups at the study end (day 21), there was no difference in cortical BMC or 
vBMD among all three groups.  Site specificity of exercised-induced bone growth in 
murine tibia has been demonstrated previously (28).  Compounded with the site 
specificity of exercise, disuse bone loss has also been shown to vary by anatomical site 
(11).  Cancellous bone compartments appear to be more pronounced targets of disuse 
bone loss, as demonstrated in both human astronaut populations and rodent studies (11, 
16, 24).          
 The most important findings of this study were that exercise, both running and 
climbing, show some beneficial effects at both the tibia and femur metaphyses, a mixed 
bone site, as well as the tibia diaphysis.  Unlike previously published work using the 
partial weight bearing model, G/6 did not induce bone loss at the femur diaphysis in our 
study (6).  However, comparisons between our study and theirs should be made with 
caution, as different strains of mice were used.                  
Consistent with the lack of change in cortical BMC and vBMD at the femur diaphysis, 
mechanical strength at this site was not affected by loading status.  When subjected to a 
three-point bending test to fracture, no significant differences were found between 
groups.  It is likely that neither the prescribed treadmill running nor tower climbing 
provided a potent enough stimulus to affect the femur diaphysis.  Future studies should 
investigate the efficacy of a combined program incorporating both a resistance and 
aerobic component to mitigate or prevent disuse bone loss in the femur.     
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 The largest physiological loads imparted on bone occur via tensile forces 
produced by contracting muscles during exercise (29).  This external stimulus is 
transduced by osteocytes and, via decreased sclerostin expression, upregulates Wnt 
signaling (20) which activate osteoblast activity and new bone formation, with  a 
consequent increase in bone mass, geometry, and strength (8).  This external relationship 
between muscle and bone makes up, in part, the functional muscle-bone unit (21). In this 
study, mineralizing activity (%MS/BS) was highest on the endocortical and periosteal 
surfaces of the tibia diaphysis of G/6+CLB.  This increase in %MS/BS versus G/6+RUN 
and G/6 may be attributed to the muscle-bone unit, since resistance exercise is known to 
produce large muscle contractions.  Increased mineralized surface of G/6+CLB at the 
tibia diaphysis (endocortical, +633%; periosteal, +935%; vs. G/6) corresponds with an 
increase in total vBMD at this site, even in the context of a partial weight bearing 
environment, suggesting that bone formation rate was higher with resistance exercise.  
We were not capable of quantifying BFR, however, due to an absence of double label.  It 
is likely that mineralization either began or ended in the window of time between 
injections of our fluorochrome label. 
 This study is not without limitations.  Unlike the hindlimb unloaded (HU) rodent 
model, which imparts a cephalic fluid shift, this partial weight bearing model does not 
alter the distribution of fluids throughout the body.  Bone loss in the lower limbs of 
animals subjected to HU is considered to be partially attributed to decreased fluid flow 
to those bones.  However, even in the absence of a cephalic fluid shift, G/6 animals did 
experience declines in bone mineral content and in an important index of osteoblast 
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activity. A second limitation to our study is the lack of ambulatory jacketed controls to 
test whether or not stress from the apparatus itself was a contributing factor to the 
deleterious effects on bone. Thirdly, animals in exercise groups were subjected to full 
weight bearing for approximately one hour each exercise day (5 times/week) and brief 
anesthesia, whereas non-exercising animals were not.  In the future, it may be 
appropriate to equate the period of full weight bearing ambulation and anesthesia 
exposure in all groups.   
In summary, our hypothesis that resistance and aerobic exercise would mitigate 
disuse-induced bone loss was satisfied.  Furthermore, resistance exercise, because of its 
ability to significantly increase bone formation in the diaphysis, may perhaps be more 
favorable than aerobic training in terms of osteogenic responsiveness. With future 
aspirations of exploring and inhabiting partial gravity planetary surfaces, these results 
have profound implications for the importance of increased mechanical loading on bone 
health.  The most profound response to exercise in BALB/cByJ mice appears to take 
place at the tibia diaphysis.  Other bone sites, such as the femur diaphysis, may require a 
more potent stimulus than the ones presented here to protect against bone loss from 
reduced mechanical loading.  Overall, our study has demonstrated that during a period of 
disuse, both resistance and aerobic exercise can partially mitigate losses in bone.   
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Table 1.  Changes in In Vivo Proximal and Mid-Diaphysis Tibia Densitometry  
 
 
Values presented as mean ± standard error of the mean (SE).  * indicates significant 
effect of time within group (p<0.05). # indicates significantly different from G/6 post 
(p<0.05).  BMC, bone mineral content; vBMD, volumetric bone mineral density  
 
  
Pre 
(Day 0)
Post 
(Day 21)
Pre 
(Day 0)
Post 
(Day 21)
Pre 
(Day 0)
Post 
(Day 21)
Proximal Tibia Metaphysis
Total BMC (mg) 1.55 ± 0.15 1.40 ± 0.08 1.56 ± 0.05 1.41 ± 0.02 1.67 ± 0.05 1.51 ± 0.03
Total vBMD (mg/cm3) 714.6 ± 44.0 564.8 ± 12.2 * 666.5 ± 11.9 635.0 ± 8.7 *# 679.5 ± 9.3 630.8 ± 11.7 *#
Total Area (mm2) 2.26 ±  0.32 2.50 ± 0.17 2.36 ± 0.11 2.22 ± 0.02 2.46 ±  0.09 2.41 ± 0.09
Marrow Area  (mm2) 1.12 ± 0.22 1.45 ± 0.12 1.18 ± 0.08 1.20 ± 0.03 1.22 ± 0.06 1.29 ± 0.07
Cort vBMD (mg/cm3) 700.4 ± 35.5 578.2 ± 11.0 * 668.4 ± 10.9 641.9 ± 7.2 # 676.1 ± 7.9 636.6 ± 10.4 *#
Tibia Mid-Diaphysis
Cort BMC (mg) 0.90 ± 0.04 0.93 ± 0.02 0.88 ± 0.02 0.91 ± 0.01 0.90 ± 0.02 0.93 ± 0.02
Cort vBMD (mg/cm3) 1183.9 ± 12.2 1189.6 ± 12.1 1153.8 ± 9.2 1190.6 ± 3.0 * 1150.4 ± 11.5 1181.5 ± 6.4 *
G/6+RUN G/6+CLBG/6
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Table 2. Ex Vivo Densitometry at the Proximal and Mid-Diaphysis Femur   
 
 
 
Values are post (Day 21) presented as mean ± SE.  # indicates significantly different 
than G/6 (p<0.05).  BMC, bone mineral content; vBMD, volumetric bone mineral 
density; CSMI= cross-sectional moment of inertia 
 
 
  
G/6 G/6+RUN G/6+CLB
Femur Proximal Metaphysis
Total BMC (mg) 1.44 ± 0.07 1.64 ± 0.02 # 1.60 ± 0.03 #
Total vBMD (mg/cm3) 570.9 ± 23.5 631.9 ± 11.6 # 637.2 ± 12.6 #
Total Area (mm2) 2.53 ± 0.11 2.62 ± 0.06 2.53 ± 0.07
Marrow Area  (mm2) 1.44 ± 0.09 1.41 ± 0.06 1.33 ± 0.06
Femur Mid-Diaphysis
Cort BMC (mg) 1.33 ± 0.06 1.31 ± 0.02 1.35 ± 0.02
Cort vBMD (mg/cm3) 1312.9 ± 11.2 1324.2 ± 4.1 1326.8 ± 3.7
Cort Area  (mm2) 1.00 ± 0.04 0.99 ± 0.01 1.01 ± 0.01
CSMI (mm4) 0.19 ± 0.01 0.18 ± 0.00 0.19 ± 0.00
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Table 3. Mid-Diaphysis Femur Mechanical Properties  
 
 
Values are post (Day 21) presented as mean ± SE.  No significant differences were 
found. 
  
G/6 G/6+RUN G/6+CLB
Femur Mid-Diaphysis
Ultimate Load ( N) 12.18 ± 0.70 12.56 ± 1.15 12.74 ± 0.24
Stiffness (N/mm) 54.61 ± 2.27 53.53 ± 2.27 55.77 ± 2.46
Energy Absorbed (N·mm) 3.63 ± 0.62 3.43 ± 0.48 3.37 ± 0.34
Elastic Modulus (GPa) 6.14 ± 0.38 6.05 ± 0.25 6.16 ± 0.34
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Figure Legends 
 
Figure 1. Daily body weight of mice throughout 21-day period of partial weight bearing. 
Data points presented as mean values; standard error bars are not included for clarity of 
viewing.  No significant differences were found over time within groups. 
 
Figure 2. Effect of exercise during partial weight bearing on proximal tibia metaphysis 
vBMD.  Both resistance (G/6+CLB) and aerobic (G/6+RUN) exercise during reduced 
gravity loading mitigated total vBMD losses compared to G/6.  Values presented as 
mean percent change ((pre-post)/pre·100%) ± SE.  # indicates significantly different than 
G/6. 
 
Figure 3. Effect of exercise during partial weight bearing on tibia mid-diaphysis cortical 
vBMD.  Even in the presence of a reduced gravity environment, exercise (G/6+CLB and 
G/6+RUN) produced an anabolic response.   Values presented as mean percent change 
((pre-post)/pre·100%) ± SE.  # indicates significantly different than G/6. 
 
Figure 4: Effect of exercise during partial weight bearing on mineralizing surface 
(%MS/BS) of the tibia mid-diaphysis.  A. Endocortical and B. Periosteal %MS/BS is 
increased with resistance exercise (G/6+CLB).  Values presented as mean ± SE.  # 
indicates significantly different than G/6.  
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Figure 4. 
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